mirror of
https://github.com/msberends/AMR.git
synced 2026-11-16 00:10:57 +01:00
3.8 MiB
3.8 MiB
| 1 | guideline | version | file_desc | type | host | method | site | mo | rank_index | ab | disk_dose | breakpoint_S | breakpoint_R | is_screening | note | sheet |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin | NA | 8 | 8 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | Enterobacterales |
| 3 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin | 10 mcg | 14 | 14 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 4 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin-sulbactam | NA | 8 | 8 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | Enterobacterales |
| 5 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin-sulbactam | 10/10 mcg | 14 | 14 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 6 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin | NA | 8 | 8 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | Enterobacterales |
| 7 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin | / mcg | Note | Note | FALSE | [C] Susceptibility inferred from ampicillin. | Enterobacterales |
| 8 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | NA | 8 | 8 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 9 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | 20/10 mcg | 19 | 19 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 10 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | NA | 32 | 32 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 11 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | 20/10 mcg | 16 | 16 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 12 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin | NA | 8 | 16 | FALSE | NA | Enterobacterales |
| 13 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin | 30 mcg | 20 | 17 | FALSE | NA | Enterobacterales |
| 14 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin-tazobactam | NA | 8 | 16 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 15 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin-tazobactam | 30/6 mcg | 20 | 17 | FALSE | NA | Enterobacterales |
| 16 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin | NA | 8 | 16 | FALSE | NA | Enterobacterales |
| 17 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin | 75 mcg | 23 | 20 | FALSE | NA | Enterobacterales |
| 18 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | NA | 8 | 16 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 19 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | 75/10 mcg | 23 | 20 | FALSE | NA | Enterobacterales |
| 20 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Temocillin | NA | Note | Note | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 21 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Temocillin | NA | Note | Note | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 22 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Mecillinam (uncomplicated UTI only) | NA | 8 | 8 | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | Enterobacterales |
| 23 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Mecillinam (uncomplicated UTI only) | 10 mcg | 15 | 15 | FALSE | [D] Ignore isolated colonies within the inhibition zone for E. coli. | Enterobacterales |
| 24 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | Enterobacterales |
| 25 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | 30 mcg | 12 | 12 | FALSE | NA | Enterobacterales |
| 26 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | Enterobacterales |
| 27 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | 30 mcg | 14 | 14 | FALSE | NA | Enterobacterales |
| 28 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefepime | NA | 1 | 4 | FALSE | NA | Enterobacterales |
| 29 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefepime | 30 mcg | 27 | 24 | FALSE | NA | Enterobacterales |
| 30 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | NA | 1 | 1 | FALSE | NA | Enterobacterales |
| 31 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | 5 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 32 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefotaxime | NA | 1 | 2 | FALSE | NA | Enterobacterales |
| 33 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefotaxime | 5 mcg | 20 | 17 | FALSE | NA | Enterobacterales |
| 34 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefoxitin (screen) | 30 mcg | 19 | 19 | FALSE | [2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type. | Enterobacterales |
| 35 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | NA | 1 | 1 | FALSE | NA | Enterobacterales |
| 36 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | 10 mcg | 21 | 21 | FALSE | NA | Enterobacterales |
| 37 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftaroline | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 38 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftaroline | 5 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 39 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime | NA | 1 | 4 | FALSE | NA | Enterobacterales |
| 40 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime | 10 mcg | 22 | 19 | FALSE | NA | Enterobacterales |
| 41 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime-avibactam | NA | 8 | 8 | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 42 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime-avibactam | 10/4 mcg | 13 | 13 | FALSE | NA | Enterobacterales |
| 43 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftibuten (UTI only) | NA | 1 | 1 | FALSE | NA | Enterobacterales |
| 44 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftibuten (UTI only) | 30 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 45 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftobiprole | NA | 0.25 | 0.25 | FALSE | NA | Enterobacterales |
| 46 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftobiprole | 5 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 47 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftolozane-tazobactam | NA | 1 | 1 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 48 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftolozane-tazobactam | 30/10 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 49 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftriaxone | NA | 1 | 2 | FALSE | NA | Enterobacterales |
| 50 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftriaxone | 30 mcg | 25 | 22 | FALSE | NA | Enterobacterales |
| 51 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime iv | NA | 8 | 8 | FALSE | NA | Enterobacterales |
| 52 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime iv | 30 mcg | 19 | 19 | FALSE | NA | Enterobacterales |
| 53 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime oral (uncomplicated UTI only) | NA | 8 | 8 | FALSE | NA | Enterobacterales |
| 54 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime oral (uncomplicated UTI only) | 30 mcg | 19 | 19 | FALSE | NA | Enterobacterales |
| 55 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 56 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ertapenem | 10 mcg | 25 | 25 | FALSE | NA | Enterobacterales |
| 57 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem | NA | 2 | 4 | FALSE | NA | Enterobacterales |
| 58 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem | 10 mcg | 22 | 17 | FALSE | NA | Enterobacterales |
| 59 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Morganella morganii,Proteus spp. and Providencia spp. | NA | Imipenem | NA | 0.125 | 4 | FALSE | [2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem. | Enterobacterales |
| 60 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Morganella morganii,Proteus spp. and Providencia spp. | NA | Imipenem | 10 mcg | 50 | 17 | FALSE | [2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem. | Enterobacterales |
| 61 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Enterobacterales |
| 62 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem | 10 mcg | 22 | 16 | FALSE | NA | Enterobacterales |
| 63 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem-vaborbactam | NA | 8 | 8 | FALSE | [3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 64 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem-vaborbactam | IP mcg | IP | IP | FALSE | NA | Enterobacterales |
| 65 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Aztreonam | NA | 1 | 4 | FALSE | [1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes. | Enterobacterales |
| 66 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Aztreonam | 30 mcg | 26 | 21 | FALSE | [1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes. | Enterobacterales |
| 67 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ciprofloxacin | NA | 0.25 | 0.5 | FALSE | NA | Enterobacterales |
| 68 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ciprofloxacin | 5 mcg | 25 | 22 | FALSE | NA | Enterobacterales |
| 69 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Salmonella spp. | NA | Ciprofloxacin | NA | 0.06 | 0.06 | FALSE | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 70 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Salmonella spp. | NA | Ciprofloxacin | NA | Note | Note | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 71 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Salmonella spp. | NA | Pefloxacin (screen) | 5 mcg | 24 | 24 | FALSE | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 72 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Levofloxacin | NA | 0.5 | 1 | FALSE | NA | Enterobacterales |
| 73 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Levofloxacin | 5 mcg | 23 | 19 | FALSE | NA | Enterobacterales |
| 74 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Moxifloxacin | NA | 0.25 | 0.25 | FALSE | NA | Enterobacterales |
| 75 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Moxifloxacin | 5 mcg | 22 | 22 | FALSE | NA | Enterobacterales |
| 76 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | NA | 0.5 | 1 | FALSE | NA | Enterobacterales |
| 77 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | 10 mcg | 22 | 19 | FALSE | NA | Enterobacterales |
| 78 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ofloxacin | NA | 0.25 | 0.5 | FALSE | NA | Enterobacterales |
| 79 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ofloxacin | 5 mcg | 24 | 22 | FALSE | NA | Enterobacterales |
| 80 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amikacin | NA | 8 | 16 | FALSE | NA | Enterobacterales |
| 81 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amikacin | 30 mcg | 18 | 15 | FALSE | NA | Enterobacterales |
| 82 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Gentamicin | NA | 2 | 4 | FALSE | NA | Enterobacterales |
| 83 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Gentamicin | 10 mcg | 17 | 14 | FALSE | NA | Enterobacterales |
| 84 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Netilmicin | NA | 2 | 4 | FALSE | NA | Enterobacterales |
| 85 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Netilmicin | 10 mcg | 15 | 12 | FALSE | NA | Enterobacterales |
| 86 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Tobramycin | NA | 2 | 4 | FALSE | NA | Enterobacterales |
| 87 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Tobramycin | 10 mcg | 17 | 14 | FALSE | NA | Enterobacterales |
| 88 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli | NA | Eravacycline | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 89 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli | NA | Eravacycline | IP mcg | IP | IP | FALSE | NA | Enterobacterales |
| 90 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli and C. koseri | NA | Tigecycline | NA | 0.5 | 0.5 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 91 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli and C. koseri | NA | Tigecycline | 15 mcg | 18 | 18 | FALSE | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method. | Enterobacterales |
| 92 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | Enterobacterales |
| 93 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Chloramphenicol | 30 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 94 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Colistin | NA | 2 | 2 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Enterobacterales |
| 95 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Colistin | NA | Note | Note | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Enterobacterales |
| 96 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin iv | NA | 32 | 32 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Enterobacterales |
| 97 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin iv | 200 mcg | 24 | 24 | FALSE | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 98 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | NA | 32 | 32 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Enterobacterales |
| 99 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | 200 mcg | 24 | 24 | FALSE | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 100 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | FALSE | NA | Enterobacterales |
| 101 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 11 | 11 | FALSE | NA | Enterobacterales |
| 102 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli | NA | Nitroxoline (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | Enterobacterales |
| 103 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli | NA | Nitroxoline (uncomplicated UTI only) | 30 mcg | 15 | 15 | FALSE | NA | Enterobacterales |
| 104 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | NA | 2 | 4 | FALSE | NA | Enterobacterales |
| 105 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | 18 | 15 | FALSE | NA | Enterobacterales |
| 106 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | FALSE | [3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterobacterales |
| 107 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 14 | 11 | FALSE | [3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterobacterales |
| 108 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin | NA | 16 | 16 | FALSE | NA | Pseudomonas |
| 109 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin | 30 mcg | 18 | 18 | FALSE | NA | Pseudomonas |
| 110 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | NA | 16 | 16 | FALSE | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 111 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | 30/6 mcg | 18 | 18 | FALSE | NA | Pseudomonas |
| 112 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin | NA | 16 | 16 | FALSE | NA | Pseudomonas |
| 113 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin | 75 mcg | 18 | 18 | FALSE | NA | Pseudomonas |
| 114 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | NA | 16 | 16 | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Pseudomonas |
| 115 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | 75/10 mcg | 18 | 18 | FALSE | NA | Pseudomonas |
| 116 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Cefepime | NA | 8 | 8 | FALSE | NA | Pseudomonas |
| 117 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Cefepime | 30 mcg | 21 | 21 | FALSE | NA | Pseudomonas |
| 118 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftazidime | NA | 8 | 8 | FALSE | NA | Pseudomonas |
| 119 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftazidime | 10 mcg | 17 | 17 | FALSE | NA | Pseudomonas |
| 120 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | P. aeruginosa | NA | Ceftazidime-avibactam | NA | 8 | 8 | FALSE | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 121 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | P. aeruginosa | NA | Ceftazidime-avibactam | 10/4 mcg | 17 | 17 | FALSE | NA | Pseudomonas |
| 122 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Pseudomonas |
| 123 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Pseudomonas |
| 124 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | P. aeruginosa | NA | Ceftolozane-tazobactam | NA | 4 | 4 | FALSE | [2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 125 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | P. aeruginosa | NA | Ceftolozane-tazobactam | 30/10 mcg | 24 | 24 | FALSE | NA | Pseudomonas |
| 126 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Imipenem | NA | 4 | 4 | FALSE | NA | Pseudomonas |
| 127 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Imipenem | 10 mcg | 20 | 20 | FALSE | NA | Pseudomonas |
| 128 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Pseudomonas |
| 129 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Meropenem | 10 mcg | 24 | 18 | FALSE | NA | Pseudomonas |
| 130 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | P. aeruginosa | NA | Meropenem-vaborbactam | NA | 8 | 8 | FALSE | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 131 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | P. aeruginosa | NA | Meropenem-vaborbactam | IP mcg | IP | IP | FALSE | NA | Pseudomonas |
| 132 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Aztreonam | NA | 16 | 16 | FALSE | NA | Pseudomonas |
| 133 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Aztreonam | 30 mcg | 18 | 18 | FALSE | NA | Pseudomonas |
| 134 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ciprofloxacin | NA | 0.5 | 0.5 | FALSE | NA | Pseudomonas |
| 135 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ciprofloxacin | 5 mcg | 26 | 26 | FALSE | NA | Pseudomonas |
| 136 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Levofloxacin | NA | 1 | 1 | FALSE | NA | Pseudomonas |
| 137 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Levofloxacin | 5 mcg | 22 | 22 | FALSE | NA | Pseudomonas |
| 138 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Amikacin | NA | 8 | 16 | FALSE | NA | Pseudomonas |
| 139 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Amikacin | 30 mcg | 18 | 15 | FALSE | NA | Pseudomonas |
| 140 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Gentamicin | NA | 4 | 4 | FALSE | NA | Pseudomonas |
| 141 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Gentamicin | 10 mcg | 15 | 15 | FALSE | NA | Pseudomonas |
| 142 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Netilmicin | NA | 4 | 4 | FALSE | NA | Pseudomonas |
| 143 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Netilmicin | 10 mcg | 12 | 12 | FALSE | NA | Pseudomonas |
| 144 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Tobramycin | NA | 4 | 4 | FALSE | NA | Pseudomonas |
| 145 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Tobramycin | 10 mcg | 16 | 16 | FALSE | NA | Pseudomonas |
| 146 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Colistin | NA | 2 | 2 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Pseudomonas |
| 147 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Colistin | NA | Note | Note | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Pseudomonas |
| 148 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | NA | 4 | 4 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.maltophilia |
| 149 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 16 | 16 | FALSE | [A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.maltophilia |
| 150 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 151 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 152 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 153 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 154 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 155 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 156 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 157 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 158 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Acinetobacter |
| 159 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Acinetobacter |
| 160 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Imipenem | NA | 2 | 4 | FALSE | NA | Acinetobacter |
| 161 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Imipenem | 10 mcg | 24 | 21 | FALSE | NA | Acinetobacter |
| 162 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Acinetobacter |
| 163 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem | 10 mcg | 21 | 15 | FALSE | NA | Acinetobacter |
| 164 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 165 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 166 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ciprofloxacin | NA | 0.06 | 1 | FALSE | NA | Acinetobacter |
| 167 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ciprofloxacin | 5 mcg | 50 | 21 | FALSE | NA | Acinetobacter |
| 168 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Levofloxacin | NA | 0.5 | 1 | FALSE | NA | Acinetobacter |
| 169 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Levofloxacin | 5 mcg | 23 | 20 | FALSE | NA | Acinetobacter |
| 170 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Amikacin | NA | 8 | 16 | FALSE | NA | Acinetobacter |
| 171 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Amikacin | 30 mcg | 19 | 17 | FALSE | NA | Acinetobacter |
| 172 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Gentamicin | NA | 4 | 4 | FALSE | NA | Acinetobacter |
| 173 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Gentamicin | 10 mcg | 17 | 17 | FALSE | NA | Acinetobacter |
| 174 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Netilmicin | NA | 4 | 4 | FALSE | NA | Acinetobacter |
| 175 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Netilmicin | 10 mcg | 16 | 16 | FALSE | NA | Acinetobacter |
| 176 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tobramycin | NA | 4 | 4 | FALSE | NA | Acinetobacter |
| 177 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tobramycin | 10 mcg | 17 | 17 | FALSE | NA | Acinetobacter |
| 178 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Eravacycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 179 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Eravacycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 180 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Minocycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 181 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Minocycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 182 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tigecycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 183 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tigecycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 184 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Colistin | NA | 2 | 2 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Acinetobacter |
| 185 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Colistin | NA | Note | Note | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Acinetobacter |
| 186 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Acinetobacter |
| 187 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 14 | 11 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Acinetobacter |
| 188 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ampicillin | NA | 4 | 8 | FALSE | NA | Enterococcus |
| 189 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ampicillin | 2 mcg | 10 | 8 | FALSE | NA | Enterococcus |
| 190 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ampicillin-sulbactam | NA | 4 | 8 | FALSE | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 191 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 192 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amoxicillin | NA | 4 | 8 | FALSE | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 193 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amoxicillin | NA | Note | Note | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 194 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | NA | 4 | 8 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 195 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 196 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Piperacillin | NA | Note | Note | FALSE | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 197 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Piperacillin | NA | Note | Note | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 198 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 199 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 200 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Imipenem | NA | 4 | 8 | FALSE | NA | Enterococcus |
| 201 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Imipenem | 10 mcg | 21 | 18 | FALSE | NA | Enterococcus |
| 202 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 203 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | 5 mcg | 15 | 15 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 204 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 205 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | 5 mcg | 15 | 15 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 206 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Norfloxacin (screen) | 10 mcg | 12 | 12 | FALSE | [B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. | Enterococcus |
| 207 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amikacin | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 208 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amikacin | NA | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 209 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 210 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | 30 mcg | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 211 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Netilmicin | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 212 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Netilmicin | NA | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 213 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | NA | Note | Note | FALSE | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 214 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | 300 mcg | Note | Note | FALSE | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 215 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tobramycin | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 216 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tobramycin | NA | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 217 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Dalbavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 218 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Dalbavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 219 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Oritavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 220 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Oritavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 221 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Teicoplanin | NA | 2 | 2 | FALSE | NA | Enterococcus |
| 222 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Teicoplanin | 30 mcg | 16 | 16 | FALSE | NA | Enterococcus |
| 223 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Telavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 224 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Telavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 225 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Vancomycin | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 226 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Vancomycin | 5 mcg | 12 | 12 | FALSE | [A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation. | Enterococcus |
| 227 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. faecium | NA | Quinupristin-dalfopristin | NA | 1 | 4 | FALSE | NA | Enterococcus |
| 228 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. faecium | NA | Quinupristin-dalfopristin | 15 mcg | 22 | 20 | FALSE | NA | Enterococcus |
| 229 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Eravacycline | NA | 0.125 | 0.125 | FALSE | NA | Enterococcus |
| 230 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Eravacycline | IP mcg | IP | IP | FALSE | NA | Enterococcus |
| 231 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tigecycline | NA | 0.25 | 0.25 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 232 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tigecycline | 15 mcg | 18 | 18 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 233 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Linezolid | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 234 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Linezolid | 10 mcg | 19 | 19 | FALSE | NA | Enterococcus |
| 235 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tedizolid | NA | IE | IE | FALSE | NA | Enterococcus |
| 236 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tedizolid | NA | IE | IE | FALSE | NA | Enterococcus |
| 237 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Daptomycin | NA | IE | IE | FALSE | [1] For more information, see http://www.eucast.org/guidance_documents/. | Enterococcus |
| 238 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Daptomycin | NA | IE | IE | FALSE | [1] For more information, see http://www.eucast.org/guidance_documents/. | Enterococcus |
| 239 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. faecalis | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | FALSE | NA | Enterococcus |
| 240 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. faecalis | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 15 | 15 | FALSE | NA | Enterococcus |
| 241 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | FALSE | NA | Enterococcus |
| 242 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | FALSE | NA | Enterococcus |
| 243 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | Note | Note | FALSE | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 244 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | Note | Note | FALSE | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 245 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | NA | Note | Note | FALSE | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterococcus |
| 246 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | Note | Note | FALSE | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterococcus |
| 247 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | NA | 0.25 | 0.25 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 248 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | 1 unit | 18 | 18 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 249 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ampicillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 250 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ampicillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 251 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 252 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 253 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 254 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 255 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 256 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 257 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Piperacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 258 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Piperacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 259 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 260 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 261 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 262 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 263 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Cloxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 264 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Cloxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 265 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Dicloxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 266 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Dicloxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 267 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Flucloxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 268 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Flucloxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 269 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefaclor | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 270 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefaclor | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 271 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefadroxil | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 272 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefadroxil | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 273 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefalexin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 274 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefalexin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 275 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefazolin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 276 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefazolin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 277 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefepime | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 278 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefepime | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 279 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefotaxime | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 280 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefotaxime | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 281 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefpodoxime | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 282 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefpodoxime | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 283 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftaroline | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 284 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftaroline | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 285 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftibuten | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 286 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftibuten | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 287 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 288 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 289 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 290 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 291 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftriaxone | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 292 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftriaxone | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 293 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 294 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 295 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 296 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 297 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ertapenem | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 298 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ertapenem | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 299 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Imipenem | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 300 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Imipenem | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 301 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Meropenem | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 302 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Meropenem | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 303 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 304 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 305 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Levofloxacin | NA | 2 | 2 | FALSE | NA | Streptococcus A,B,C,G |
| 306 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Levofloxacin | 5 mcg | 17 | 17 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 307 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Moxifloxacin | NA | 0.5 | 0.5 | FALSE | NA | Streptococcus A,B,C,G |
| 308 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Moxifloxacin | 5 mcg | 19 | 19 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 309 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Norfloxacin (screen) | 10 mcg | 12 | Note | FALSE | [B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Streptococcus A,B,C,G |
| 310 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Dalbavancin | NA | 0.125 | 0.125 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 311 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Dalbavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 312 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Oritavancin | NA | 0.25 | 0.25 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 313 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Oritavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 314 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Teicoplanin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 315 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Teicoplanin | 30 mcg | 15 | 15 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 316 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Telavancin | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 317 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Telavancin | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 318 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 319 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Vancomycin | 5 mcg | 13 | 13 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 320 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Azithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 321 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Azithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 322 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Clarithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 323 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 324 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Erythromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 325 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Erythromycin | 15 mcg | 21 | 18 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 326 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Roxithromycin | NA | 0.5 | 1 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 327 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 328 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Telithromycin | NA | 0.25 | 0.5 | FALSE | NA | Streptococcus A,B,C,G |
| 329 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Telithromycin | 15 mcg | 20 | 17 | FALSE | NA | Streptococcus A,B,C,G |
| 330 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known. | Streptococcus A,B,C,G |
| 331 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Clindamycin | 2 mcg | 17 | 17 | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known. | Streptococcus A,B,C,G |
| 332 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 333 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 334 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Eravacycline | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 335 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Eravacycline | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 336 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Minocycline | NA | 0.5 | 1 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 337 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Minocycline | 30 mcg | 23 | 20 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 338 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 339 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tetracycline | 30 mcg | 23 | 20 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 340 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tigecycline | NA | 0.125 | 0.125 | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 341 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tigecycline | 15 mcg | 19 | 19 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 342 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Linezolid | NA | 2 | 4 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 343 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Linezolid | 10 mcg | 19 | 16 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 344 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tedizolid | NA | 0.5 | 0.5 | FALSE | [2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 345 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tedizolid | NA | Note | Note | FALSE | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 346 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | Streptococcus A,B,C,G |
| 347 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Chloramphenicol | 30 mcg | 19 | 19 | FALSE | NA | Streptococcus A,B,C,G |
| 348 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Daptomycin | NA | 1 | 1 | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 349 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Daptomycin | NA | Note | Note | FALSE | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 350 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Fusidic acid | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 351 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Fusidic acid | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 352 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. agalactiae (group B streptococci) | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | FALSE | NA | Streptococcus A,B,C,G |
| 353 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. agalactiae (group B streptococci) | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 15 | 15 | FALSE | NA | Streptococcus A,B,C,G |
| 354 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Rifampicin | NA | 0.06 | 0.5 | FALSE | NA | Streptococcus A,B,C,G |
| 355 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Rifampicin | 5 mcg | 21 | 15 | FALSE | NA | Streptococcus A,B,C,G |
| 356 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. agalactiae (group B streptococci) | NA | Trimethoprim (uncomplicated UTI only) | NA | 2 | 2 | FALSE | NA | Streptococcus A,B,C,G |
| 357 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. agalactiae (group B streptococci) | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | IP | IP | FALSE | NA | Streptococcus A,B,C,G |
| 358 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | NA | 1 | 2 | FALSE | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Streptococcus A,B,C,G |
| 359 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 18 | 15 | FALSE | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Streptococcus A,B,C,G |
| 360 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | NA | 0.06 | 2 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages. | S.pneumoniae |
| 361 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages. | S.pneumoniae |
| 362 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | NA | 0.06 | 0.06 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 363 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 364 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ampicillin | NA | 0.5 | 2 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 365 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ampicillin | 2 mcg | 22 | 16 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 366 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 367 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 368 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin iv | NA | Note | Note | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 369 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin iv | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 370 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin oral | NA | 0.5 | 1 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 371 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin oral | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 372 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | NA | Note | Note | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 373 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 374 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | NA | 0.5 | 1 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | S.pneumoniae |
| 375 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 376 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Piperacillin | NA | Note | Note | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 377 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Piperacillin | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 378 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 379 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 380 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 381 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 382 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Oxacillin (screen) | 1 mcg | 20 | Note | FALSE | [D] For interpretation of the oxacillin disk screen, see flow chart below. | S.pneumoniae |
| 383 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefaclor | NA | 0.03 | 0.5 | FALSE | NA | S.pneumoniae |
| 384 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefaclor | 30 mcg | 50 | 28 | FALSE | NA | S.pneumoniae |
| 385 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefepime | NA | 1 | 2 | FALSE | NA | S.pneumoniae |
| 386 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefepime | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 387 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefotaxime | NA | 0.5 | 2 | FALSE | NA | S.pneumoniae |
| 388 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefotaxime | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 389 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefpodoxime | NA | 0.25 | 0.5 | FALSE | NA | S.pneumoniae |
| 390 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefpodoxime | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 391 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftaroline | NA | 0.25 | 0.25 | FALSE | NA | S.pneumoniae |
| 392 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftaroline | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 393 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftobiprole | NA | 0.5 | 0.5 | FALSE | NA | S.pneumoniae |
| 394 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftobiprole | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 395 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftriaxone | NA | 0.5 | 2 | FALSE | NA | S.pneumoniae |
| 396 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftriaxone | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 397 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefuroxime iv | NA | 0.5 | 1 | FALSE | NA | S.pneumoniae |
| 398 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefuroxime iv | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 399 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefuroxime oral | NA | 0.25 | 0.5 | FALSE | NA | S.pneumoniae |
| 400 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefuroxime oral | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 401 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 402 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ertapenem | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 403 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Imipenem | NA | 2 | 2 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 404 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Imipenem | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 405 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | NA | 2 | 2 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 406 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 407 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | FALSE | [3] Meropenem is the only carbapenem used for meningitis. | S.pneumoniae |
| 408 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem(meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | [3] Meropenem is the only carbapenem used for meningitis. | S.pneumoniae |
| 409 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 410 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 411 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Levofloxacin | NA | 2 | 2 | FALSE | NA | S.pneumoniae |
| 412 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Levofloxacin | 5 mcg | 16 | 16 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 413 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Moxifloxacin | NA | 0.5 | 0.5 | FALSE | NA | S.pneumoniae |
| 414 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Moxifloxacin | 5 mcg | 22 | 22 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 415 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Norfloxacin (screen) | 10 mcg | 10 | Note | FALSE | [B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | S.pneumoniae |
| 416 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Dalbavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 417 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Dalbavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 418 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Oritavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 419 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Oritavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 420 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Teicoplanin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 421 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Teicoplanin | 30 mcg | 17 | 17 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 422 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Telavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 423 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Telavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 424 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 425 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Vancomycin | 5 mcg | 16 | 16 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 426 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Azithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 427 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Azithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 428 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Clarithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 429 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 430 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Erythromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 431 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Erythromycin | 15 mcg | 22 | 19 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 432 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Roxithromycin | NA | 0.5 | 1 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 433 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 434 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Telithromycin | NA | 0.25 | 0.5 | FALSE | NA | S.pneumoniae |
| 435 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Telithromycin | 15 mcg | 23 | 20 | FALSE | NA | S.pneumoniae |
| 436 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | S.pneumoniae |
| 437 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Clindamycin | 2 mcg | 19 | 19 | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | S.pneumoniae |
| 438 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 439 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 440 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Eravacycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 441 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Eravacycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 442 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Minocycline | NA | 0.5 | 1 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 443 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Minocycline | 30 mcg | 24 | 21 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 444 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 445 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tetracycline | 30 mcg | 25 | 22 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 446 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tigecycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 447 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tigecycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 448 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Linezolid | NA | 2 | 4 | FALSE | NA | S.pneumoniae |
| 449 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Linezolid | 10 mcg | 22 | 19 | FALSE | NA | S.pneumoniae |
| 450 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tedizolid | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 451 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tedizolid | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 452 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | S.pneumoniae |
| 453 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Chloramphenicol | 30 mcg | 21 | 21 | FALSE | NA | S.pneumoniae |
| 454 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Daptomycin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 455 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Daptomycin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 456 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 457 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 458 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Rifampicin | NA | 0.06 | 0.5 | FALSE | NA | S.pneumoniae |
| 459 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Rifampicin | 5 mcg | 22 | 17 | FALSE | NA | S.pneumoniae |
| 460 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | NA | 1 | 2 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.pneumoniae |
| 461 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 13 | 10 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.pneumoniae |
| 462 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Benzylpenicillin | NA | 0.25 | 2 | FALSE | NA | Viridans group streptococci |
| 463 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Benzylpenicillin | 1 unit | 18 | 12 | FALSE | NA | Viridans group streptococci |
| 464 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Benzylpenicillin (screen) | 1 unit | 18 | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 465 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ampicillin | NA | 0.5 | 2 | FALSE | NA | Viridans group streptococci |
| 466 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ampicillin | 2 mcg | 21 | 15 | FALSE | NA | Viridans group streptococci |
| 467 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 468 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 469 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amoxicillin | NA | 0.5 | 2 | FALSE | NA | Viridans group streptococci |
| 470 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Amoxicillin | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 471 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 472 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 473 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Piperacillin | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 474 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Piperacillin | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 475 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 476 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 477 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 478 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 479 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 480 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 481 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 482 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 483 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefazolin | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 484 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefazolin | 30 mcg | IP | IP | FALSE | NA | Viridans group streptococci |
| 485 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefepime | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 486 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefepime | 30 mcg | 25 | 25 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 487 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefotaxime | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 488 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefotaxime | 5 mcg | 23 | 23 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 489 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 490 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 491 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ceftriaxone | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 492 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ceftriaxone | 30 mcg | 27 | 27 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 493 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefuroxime iv | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 494 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefuroxime iv | 30 mcg | 26 | 26 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 495 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 496 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ertapenem | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 497 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Imipenem | NA | 2 | 2 | FALSE | NA | Viridans group streptococci |
| 498 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Imipenem | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 499 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Meropenem | NA | 2 | 2 | FALSE | NA | Viridans group streptococci |
| 500 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Meropenem | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 501 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 502 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 503 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Levofloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 504 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Levofloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 505 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 506 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 507 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amikacin | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 508 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 509 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Netilmicin | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 510 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tobramycin | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 511 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | NA | Dalbavancin | NA | 0.125 | 0.125 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 512 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | NA | Dalbavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 513 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | NA | Oritavancin | NA | 0.25 | 0.25 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 514 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | NA | Oritavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 515 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Teicoplanin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 516 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Teicoplanin | 30 mcg | 16 | 16 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 517 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Telavancin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 518 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Telavancin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 519 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 520 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Vancomycin | 5 mcg | 15 | 15 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 521 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Azithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 522 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Azithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 523 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Clarithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 524 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Clarithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 525 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Erythromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 526 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Erythromycin | 15 mcg | IE | IE | FALSE | NA | Viridans group streptococci |
| 527 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Roxithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 528 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Roxithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 529 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Telithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 530 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Telithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 531 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | Viridans group streptococci |
| 532 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Clindamycin | 2 mcg | 19 | 19 | FALSE | [A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | Viridans group streptococci |
| 533 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Quinupristin-dalfopristin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 534 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Quinupristin-dalfopristin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 535 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Eravacycline | NA | 0.125 | 0.125 | FALSE | NA | Viridans group streptococci |
| 536 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Eravacycline | IP mcg | IP | IP | FALSE | NA | Viridans group streptococci |
| 537 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tigecycline | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 538 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Tigecycline | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 539 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | NA | Tedizolid | NA | 0.25 | 0.25 | FALSE | NA | Viridans group streptococci |
| 540 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | NA | Tedizolid | NA | Note | Note | FALSE | [A] Perform an MIC test. | Viridans group streptococci |
| 541 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Benzylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 542 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Benzylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 543 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Benzylpenicillin (screen) | 1 unit | 12 | Note | FALSE | [1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 544 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ampicillin | NA | 1 | 1 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 545 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ampicillin | 2 mcg | 16 | 16 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 546 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ampicillin-sulbactam | NA | 1 | 1 | FALSE | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid. | H.influenzae |
| 547 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ampicillin-sulbactam | 10/10 mcg | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | H.influenzae |
| 548 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin iv | NA | 2 | 2 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 549 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin iv | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 550 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin oral | NA | 2 | 2 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 551 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin oral | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 552 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | NA | 2 | 2 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | H.influenzae |
| 553 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | 2/1 mcg | 15 | 15 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 554 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | NA | 2 | 2 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | H.influenzae |
| 555 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | 2/1 mcg | 15 | 15 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 556 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Piperacillin | NA | IE | IE | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 557 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Piperacillin | NA | IE | IE | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 558 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Piperacillin-tazobactam | NA | 0.25 | 0.25 | FALSE | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | H.influenzae |
| 559 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Piperacillin-tazobactam | 30/6 mcg | 27 | 27 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 560 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ticarcillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 561 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ticarcillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 562 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | H.influenzae |
| 563 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | H.influenzae |
| 564 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Temocillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 565 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Temocillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 566 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 567 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 568 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefepime | NA | 0.25 | 0.25 | FALSE | NA | H.influenzae |
| 569 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefepime | 30 mcg | 28 | 28 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 570 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefixime | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 571 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefixime | 5 mcg | 26 | 26 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 572 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefotaxime | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 573 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefotaxime | 5 mcg | 27 | 27 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 574 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefpodoxime | NA | 0.25 | 0.25 | FALSE | NA | H.influenzae |
| 575 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefpodoxime | 10 mcg | 26 | 26 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 576 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftaroline | NA | 0.03 | 0.03 | FALSE | NA | H.influenzae |
| 577 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftaroline | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 578 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftibuten | NA | 1 | 1 | FALSE | NA | H.influenzae |
| 579 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftibuten | 30 mcg | 25 | 25 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 580 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | H.influenzae |
| 581 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | H.influenzae |
| 582 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 583 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 584 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftriaxone | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 585 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftriaxone | 30 mcg | 32 | 32 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 586 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefuroxime iv | NA | 1 | 2 | FALSE | NA | H.influenzae |
| 587 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefuroxime iv | 30 mcg | 27 | 25 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 588 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefuroxime oral | NA | 0.125 | 1 | FALSE | NA | H.influenzae |
| 589 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefuroxime oral | 30 mcg | 50 | 27 | FALSE | NA | H.influenzae |
| 590 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 591 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ertapenem | 10 mcg | 23 | 23 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 592 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Imipenem | NA | 2 | 2 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 593 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Imipenem | 10 mcg | 20 | 20 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 594 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | NA | 2 | 2 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 595 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | 10 mcg | 20 | 20 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 596 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | FALSE | [3] Meropenem is the only carbapenem used for meningitis. | H.influenzae |
| 597 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem(meningitis) | NA | Note | Note | FALSE | [C] For use in meningitis determine the meropenem MIC value. | [3] Meropenem is the only carbapenem used for meningitis. | H.influenzae |
| 598 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 599 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 600 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Aztreonam | NA | IE | IE | FALSE | NA | H.influenzae |
| 601 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Aztreonam | NA | IE | IE | FALSE | NA | H.influenzae |
| 602 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ciprofloxacin | NA | 0.06 | 0.06 | FALSE | NA | H.influenzae |
| 603 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ciprofloxacin | 5 mcg | 30 | 30 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 604 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Levofloxacin | NA | 0.06 | 0.06 | FALSE | NA | H.influenzae |
| 605 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Levofloxacin | 5 mcg | 30 | 30 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 606 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Moxifloxacin | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 607 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Moxifloxacin | 5 mcg | 28 | 28 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 608 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Nalidixic acid (screen) | 30 mcg | 23 | Note | FALSE | [B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | H.influenzae |
| 609 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ofloxacin | NA | 0.06 | 0.06 | FALSE | NA | H.influenzae |
| 610 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ofloxacin | 5 mcg | 30 | 30 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 611 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amikacin | NA | IE | IE | FALSE | NA | H.influenzae |
| 612 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amikacin | NA | IE | IE | FALSE | NA | H.influenzae |
| 613 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Gentamicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 614 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Gentamicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 615 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Netilmicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 616 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Netilmicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 617 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tobramycin | NA | IE | IE | FALSE | NA | H.influenzae |
| 618 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tobramycin | NA | IE | IE | FALSE | NA | H.influenzae |
| 619 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Azithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 620 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Azithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 621 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Clarithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 622 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 623 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Erythromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 624 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Erythromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 625 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Roxithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 626 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 627 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Telithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 628 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Telithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 629 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 630 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 631 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Eravacycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 632 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Eravacycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 633 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Minocycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 634 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Minocycline | 30 mcg | 24 | 21 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 635 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 636 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tetracycline | 30 mcg | 25 | 22 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 637 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tigecycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 638 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tigecycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 639 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Chloramphenicol | NA | 2 | 2 | FALSE | NA | H.influenzae |
| 640 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Chloramphenicol | 30 mcg | 28 | 28 | FALSE | NA | H.influenzae |
| 641 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | H.influenzae |
| 642 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | H.influenzae |
| 643 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | NA | 1 | 1 | FALSE | NA | H.influenzae |
| 644 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | 5 mcg | 18 | 18 | FALSE | NA | H.influenzae |
| 645 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | NA | 0.5 | 1 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | H.influenzae |
| 646 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 23 | 20 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | H.influenzae |
| 647 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ampicillin-sulbactam | NA | 1 | 1 | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 648 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 649 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | NA | 1 | 1 | FALSE | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | M.catarrhalis |
| 650 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | 2/1 mcg | 19 | 19 | FALSE | NA | M.catarrhalis |
| 651 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 652 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 653 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ticarcillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 654 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ticarcillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 655 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 656 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 657 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Temocillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 658 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Temocillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 659 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefepime | NA | 4 | 4 | FALSE | NA | M.catarrhalis |
| 660 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefepime | 30 mcg | 20 | 20 | FALSE | NA | M.catarrhalis |
| 661 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefixime | NA | 0.5 | 1 | FALSE | NA | M.catarrhalis |
| 662 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefixime | 5 mcg | 21 | 18 | FALSE | NA | M.catarrhalis |
| 663 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefotaxime | NA | 1 | 2 | FALSE | NA | M.catarrhalis |
| 664 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefotaxime | 5 mcg | 20 | 17 | FALSE | NA | M.catarrhalis |
| 665 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefpodoxime | NA | IP | IP | FALSE | NA | M.catarrhalis |
| 666 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefpodoxime | 10 mcg | IP | IP | FALSE | NA | M.catarrhalis |
| 667 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftaroline | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 668 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftaroline | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 669 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftibuten | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 670 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftibuten | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 671 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 672 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 673 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 674 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 675 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftriaxone | NA | 1 | 2 | FALSE | NA | M.catarrhalis |
| 676 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftriaxone | 30 mcg | 24 | 21 | FALSE | NA | M.catarrhalis |
| 677 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefuroxime iv | NA | 4 | 8 | FALSE | NA | M.catarrhalis |
| 678 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefuroxime iv | 30 mcg | 21 | 18 | FALSE | NA | M.catarrhalis |
| 679 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefuroxime oral | NA | 0.125 | 4 | FALSE | NA | M.catarrhalis |
| 680 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefuroxime oral | 30 mcg | 50 | 21 | FALSE | NA | M.catarrhalis |
| 681 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 682 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ertapenem | 10 mcg | 29 | 29 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 683 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Imipenem | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 684 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Imipenem | 10 mcg | 29 | 29 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 685 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Meropenem | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 686 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Meropenem | 10 mcg | 33 | 33 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 687 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 688 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 689 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Aztreonam | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 690 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Aztreonam | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 691 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ciprofloxacin | NA | 0.125 | 0.125 | FALSE | NA | M.catarrhalis |
| 692 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ciprofloxacin | 5 mcg | 31 | 31 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 693 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Levofloxacin | NA | 0.125 | 0.125 | FALSE | NA | M.catarrhalis |
| 694 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Levofloxacin | 5 mcg | 29 | 29 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 695 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Moxifloxacin | NA | 0.25 | 0.25 | FALSE | NA | M.catarrhalis |
| 696 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Moxifloxacin | 5 mcg | 26 | 26 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 697 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Nalidixic acid (screen) | 30 mcg | 23 | Note | FALSE | [B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | M.catarrhalis |
| 698 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ofloxacin | NA | 0.25 | 0.25 | FALSE | NA | M.catarrhalis |
| 699 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ofloxacin | 5 mcg | 28 | 28 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 700 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Amikacin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 701 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Amikacin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 702 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Gentamicin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 703 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Gentamicin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 704 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Netilmicin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 705 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Netilmicin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 706 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Tobramycin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 707 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Tobramycin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 708 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Azithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 709 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Azithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 710 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Clarithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 711 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 712 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Erythromycin | NA | 0.25 | 0.5 | FALSE | NA | M.catarrhalis |
| 713 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Erythromycin | 15 mcg | 23 | 20 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 714 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Roxithromycin | NA | 0.5 | 1 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 715 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 716 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Telithromycin | NA | 0.25 | 0.5 | FALSE | NA | M.catarrhalis |
| 717 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Telithromycin | 15 mcg | 23 | 20 | FALSE | NA | M.catarrhalis |
| 718 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 719 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 720 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Eravacycline | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 721 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Eravacycline | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 722 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Minocycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 723 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Minocycline | 30 mcg | 25 | 22 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 724 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 725 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Tetracycline | 30 mcg | 28 | 25 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 726 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Tigecycline | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 727 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Tigecycline | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 728 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Chloramphenicol | NA | 2 | 2 | FALSE | [1] Breakpoints relate to topical use only. | M.catarrhalis |
| 729 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Chloramphenicol | 30 mcg | 30 | 30 | FALSE | [A] Breakpoints relate to topical use only. | M.catarrhalis |
| 730 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 731 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 732 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Trimethoprim-sulfamethoxazole | NA | 0.5 | 1 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | M.catarrhalis |
| 733 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 18 | 15 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | M.catarrhalis |
| 734 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Benzylpenicillin | NA | 0.06 | 1 | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 735 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ampicillin | NA | Note | Note | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 736 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ampicillin-sulbactam | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 737 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Amoxicillin | NA | Note | Note | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 738 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 739 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Temocillin | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 740 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Cefixime | NA | 0.125 | 0.125 | FALSE | NA | N.gonorrhoeae |
| 741 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Cefotaxime | NA | 0.125 | 0.125 | FALSE | NA | N.gonorrhoeae |
| 742 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ceftriaxone | NA | 0.125 | 0.125 | FALSE | NA | N.gonorrhoeae |
| 743 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ertapenem | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 744 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Imipenem | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 745 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Meropenem | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 746 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 747 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Aztreonam | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 748 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ciprofloxacin | NA | 0.03 | 0.06 | FALSE | NA | N.gonorrhoeae |
| 749 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Levofloxacin | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 750 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 751 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ofloxacin | NA | 0.125 | 0.25 | FALSE | NA | N.gonorrhoeae |
| 752 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Azithromycin | NA | Note | Note | FALSE | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L. | N.gonorrhoeae |
| 753 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Doxycycline | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 754 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Eravacycline | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 755 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Minocycline | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 756 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Tetracycline | NA | 0.5 | 1 | FALSE | NA | N.gonorrhoeae |
| 757 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Tigecycline | NA | IE | IE | FALSE | NA | N.gonorrhoeae |
| 758 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Spectinomycin | NA | 64 | 64 | FALSE | NA | N.gonorrhoeae |
| 759 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Benzylpenicillin | NA | 0.06 | 0.25 | FALSE | NA | N.meningitidis |
| 760 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Ampicillin | NA | 0.125 | 1 | FALSE | NA | N.meningitidis |
| 761 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Ampicillin-sulbactam | NA | IE | IE | FALSE | NA | N.meningitidis |
| 762 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Amoxicillin | NA | 0.125 | 1 | FALSE | NA | N.meningitidis |
| 763 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Cefotaxime | NA | 0.125 | 0.125 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | N.meningitidis |
| 764 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Ceftriaxone | NA | 0.125 | 0.125 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | N.meningitidis |
| 765 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | N.meningitidis |
| 766 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | N.meningitidis |
| 767 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Ciprofloxacin | NA | 0.03 | 0.03 | FALSE | [1] Breakpoints apply only to use in the prophylaxis of meningococcal disease. | N.meningitidis |
| 768 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Levofloxacin | NA | IE | IE | FALSE | NA | N.meningitidis |
| 769 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | N.meningitidis |
| 770 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Ofloxacin | NA | IE | IE | FALSE | NA | N.meningitidis |
| 771 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Eravacycline | NA | IE | IE | FALSE | NA | N.meningitidis |
| 772 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Minocycline | NA | 1 | 2 | FALSE | [1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections. | N.meningitidis |
| 773 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections. | N.meningitidis |
| 774 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Tigecycline | NA | IE | IE | FALSE | NA | N.meningitidis |
| 775 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Chloramphenicol | NA | 2 | 2 | FALSE | NA | N.meningitidis |
| 776 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria meningitidis | NA | Rifampicin | NA | 0.25 | 0.25 | FALSE | [1] For prophylaxis of meningitis only (refer to national guidelines). | N.meningitidis |
| 777 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Benzylpenicillin | NA | 0.25 | 0.5 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Grampositive |
| 778 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ampicillin | NA | 4 | 8 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Grampositive |
| 779 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ampicillin-sulbactam | NA | 4 | 8 | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | Anaerobes, Grampositive |
| 780 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Amoxicillin | NA | 4 | 8 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Grampositive |
| 781 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Amoxicillin-clavulanic acid | NA | 4 | 8 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Anaerobes, Grampositive |
| 782 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Piperacillin | NA | 8 | 16 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Grampositive |
| 783 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Piperacillin-tazobactam | NA | 8 | 16 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Anaerobes, Grampositive |
| 784 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ticarcillin | NA | 8 | 16 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Grampositive |
| 785 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ticarcillin-clavulanic acid | NA | 8 | 16 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Anaerobes, Grampositive |
| 786 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 787 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Cefoxitin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 788 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 789 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | Anaerobes, Grampositive |
| 790 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Imipenem | NA | 2 | 4 | FALSE | NA | Anaerobes, Grampositive |
| 791 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Anaerobes, Grampositive |
| 792 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 793 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 794 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Dalbavancin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 795 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Oritavancin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 796 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Teicoplanin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 797 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Telavancin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 798 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Vancomycin | NA | 2 | 2 | FALSE | NA | Anaerobes, Grampositive |
| 799 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Erythromycin | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 800 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Clindamycin | NA | 4 | 4 | FALSE | NA | Anaerobes, Grampositive |
| 801 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Doxycycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Grampositive |
| 802 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Eravacycline | NA | IE | IE | FALSE | NA | Anaerobes, Grampositive |
| 803 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Minocycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Grampositive |
| 804 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Tetracycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Grampositive |
| 805 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Tigecycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Grampositive |
| 806 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | Anaerobes, Grampositive |
| 807 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Metronidazole | NA | 4 | 4 | FALSE | NA | Anaerobes, Grampositive |
| 808 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Clostridioides difficile | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes. | C.difficile |
| 809 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Clostridioides difficile | NA | Fidaxomicin | NA | IE | IE | FALSE | [4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies. | C.difficile |
| 810 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Clostridioides difficile | NA | Metronidazole | NA | 2 | 2 | FALSE | [5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes. | C.difficile |
| 811 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Benzylpenicillin | NA | 0.25 | 0.5 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Gramnegative |
| 812 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Ampicillin | NA | 0.5 | 2 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Gramnegative |
| 813 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Ampicillin-sulbactam | NA | 4 | 8 | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | Anaerobes, Gramnegative |
| 814 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Amoxicillin | NA | 0.5 | 2 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Gramnegative |
| 815 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Amoxicillin-clavulanic acid | NA | 4 | 8 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Anaerobes, Gramnegative |
| 816 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Piperacillin | NA | 16 | 16 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Gramnegative |
| 817 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Piperacillin-tazobactam | NA | 8 | 16 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Anaerobes, Gramnegative |
| 818 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Ticarcillin | NA | 16 | 16 | FALSE | [1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin. | Anaerobes, Gramnegative |
| 819 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Ticarcillin-clavulanic acid | NA | 8 | 16 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Anaerobes, Gramnegative |
| 820 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 821 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Cefoxitin | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 822 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 823 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | Anaerobes, Gramnegative |
| 824 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Imipenem | NA | 2 | 4 | FALSE | NA | Anaerobes, Gramnegative |
| 825 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Anaerobes, Gramnegative |
| 826 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 827 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 828 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Erythromycin | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 829 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Clindamycin | NA | 4 | 4 | FALSE | NA | Anaerobes, Gramnegative |
| 830 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Doxycycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Gramnegative |
| 831 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Eravacycline | NA | IE | IE | FALSE | NA | Anaerobes, Gramnegative |
| 832 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Minocycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Gramnegative |
| 833 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Tetracycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Gramnegative |
| 834 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Tigecycline | NA | Note | Note | FALSE | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given. | Anaerobes, Gramnegative |
| 835 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | Anaerobes, Gramnegative |
| 836 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Gram-negative anaerobes | NA | Metronidazole | NA | 4 | 4 | FALSE | NA | Anaerobes, Gramnegative |
| 837 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Helicobacter pylori | NA | Amoxicillin | NA | 0.125 | 0.125 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility. | H.pylori |
| 838 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Helicobacter pylori | NA | Levofloxacin | NA | 1 | 1 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility. | H.pylori |
| 839 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Helicobacter pylori | NA | Clarithromycin | NA | 0.25 | 0.5 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility. | H.pylori |
| 840 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Helicobacter pylori | NA | Tetracycline | NA | 1 | 1 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility. | H.pylori |
| 841 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Helicobacter pylori | NA | Metronidazole | NA | 8 | 8 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility. | H.pylori |
| 842 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Helicobacter pylori | NA | Rifampicin | NA | 1 | 1 | FALSE | [1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility. | H.pylori |
| 843 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Benzylpenicillin | NA | 1 | 1 | FALSE | NA | L.monocytogenes |
| 844 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Benzylpenicillin | 1 unit | 13 | 13 | FALSE | NA | L.monocytogenes |
| 845 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Ampicillin | NA | 1 | 1 | FALSE | NA | L.monocytogenes |
| 846 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Ampicillin | 2 mcg | 16 | 16 | FALSE | NA | L.monocytogenes |
| 847 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Meropenem | NA | 0.25 | 0.25 | FALSE | NA | L.monocytogenes |
| 848 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Meropenem | 10 mcg | 26 | 26 | FALSE | NA | L.monocytogenes |
| 849 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Erythromycin | NA | 1 | 1 | FALSE | NA | L.monocytogenes |
| 850 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Erythromycin | 15 mcg | 25 | 25 | FALSE | NA | L.monocytogenes |
| 851 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Trimethoprim-sulfamethoxazole | NA | 0.06 | 0.06 | FALSE | [1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | L.monocytogenes |
| 852 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 29 | 29 | FALSE | [1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | L.monocytogenes |
| 853 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Benzylpenicillin | NA | 0.5 | 0.5 | FALSE | NA | P.multocida |
| 854 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Benzylpenicillin | 1 unit | 17 | 17 | FALSE | NA | P.multocida |
| 855 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Ampicillin | NA | 1 | 1 | FALSE | NA | P.multocida |
| 856 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Ampicillin | NA | Note | Note | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | P.multocida |
| 857 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Amoxicillin | NA | 1 | 1 | FALSE | NA | P.multocida |
| 858 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Amoxicillin | NA | Note | Note | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | P.multocida |
| 859 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Amoxicillin-clavulanic acid | NA | 1 | 1 | FALSE | [1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | P.multocida |
| 860 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Amoxicillin-clavulanic acid | 2/1 mcg | 15 | 15 | FALSE | NA | P.multocida |
| 861 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Cefotaxime | NA | 0.03 | 0.03 | FALSE | NA | P.multocida |
| 862 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Cefotaxime | 5 mcg | 26 | 26 | FALSE | NA | P.multocida |
| 863 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Ciprofloxacin | NA | 0.06 | 0.06 | FALSE | NA | P.multocida |
| 864 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Ciprofloxacin | 5 mcg | 27 | 27 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | P.multocida |
| 865 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Levofloxacin | NA | 0.06 | 0.06 | FALSE | NA | P.multocida |
| 866 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Levofloxacin | 5 mcg | 27 | 27 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | P.multocida |
| 867 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Nalidixic acid (screen) | 30 mcg | 23 | Note | FALSE | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | P.multocida |
| 868 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Doxycycline | NA | 1 | 1 | FALSE | NA | P.multocida |
| 869 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Doxycycline | NA | Note | Note | FALSE | [A] Susceptibility inferred from tetracycline screen test. | P.multocida |
| 870 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Tetracycline (screen) | 30 mcg | 24 | 24 | FALSE | [A] Susceptibility inferred from tetracycline screen test. | P.multocida |
| 871 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Trimethoprim-sulfamethoxazole | NA | 0.25 | 0.25 | FALSE | [1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | P.multocida |
| 872 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 23 | 23 | FALSE | [1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | P.multocida |
| 873 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Ciprofloxacin | NA | 0.5 | 0.5 | FALSE | NA | C.jejuni_C.coli |
| 874 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Ciprofloxacin | 5 mcg | 26 | 26 | FALSE | NA | C.jejuni_C.coli |
| 875 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Azithromycin | NA | Note | Note | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 876 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Azithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 877 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Clarithromycin | NA | Note | Note | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 878 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 879 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | C. jejuni | NA | Erythromycin | NA | 4 | 4 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 880 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | C. jejuni | NA | Erythromycin | 15 mcg | 20 | 20 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 881 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | C. coli | NA | Erythromycin | NA | 8 | 8 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 882 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | C. coli | NA | Erythromycin | 15 mcg | 24 | 24 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 883 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Doxycycline | NA | Note | Note | FALSE | [1] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 884 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Doxycycline | NA | Note | Note | FALSE | [A] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 885 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Tetracycline | NA | 2 | 2 | FALSE | [1] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 886 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Tetracycline | 30 mcg | 30 | 30 | FALSE | [A] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 887 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Benzylpenicillin | NA | 0.125 | 0.125 | FALSE | NA | Corynebacterium |
| 888 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Benzylpenicillin | 1 unit | 29 | 29 | FALSE | NA | Corynebacterium |
| 889 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Ciprofloxacin | NA | 1 | 1 | FALSE | NA | Corynebacterium |
| 890 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Ciprofloxacin | 5 mcg | 25 | 25 | FALSE | NA | Corynebacterium |
| 891 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Moxifloxacin | NA | 0.5 | 0.5 | FALSE | NA | Corynebacterium |
| 892 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Moxifloxacin | 5 mcg | 25 | 25 | FALSE | NA | Corynebacterium |
| 893 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Gentamicin | NA | 1 | 1 | FALSE | NA | Corynebacterium |
| 894 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Gentamicin | 10 mcg | 23 | 23 | FALSE | NA | Corynebacterium |
| 895 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Vancomycin | NA | 2 | 2 | FALSE | NA | Corynebacterium |
| 896 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Vancomycin | 5 mcg | 17 | 17 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | Corynebacterium |
| 897 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Erythromycin | NA | IP | IP | FALSE | NA | Corynebacterium |
| 898 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Erythromycin | 15 mcg | IP | IP | FALSE | NA | Corynebacterium |
| 899 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | NA | Corynebacterium |
| 900 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Clindamycin | 2 mcg | 20 | 20 | FALSE | NA | Corynebacterium |
| 901 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Tetracycline | NA | 2 | 2 | FALSE | NA | Corynebacterium |
| 902 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Tetracycline | 30 mcg | 24 | 24 | FALSE | NA | Corynebacterium |
| 903 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Linezolid | NA | 2 | 2 | FALSE | NA | Corynebacterium |
| 904 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Linezolid | 10 mcg | 25 | 25 | FALSE | NA | Corynebacterium |
| 905 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Rifampicin | NA | 0.06 | 0.5 | FALSE | NA | Corynebacterium |
| 906 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Rifampicin | 5 mcg | 30 | 25 | FALSE | NA | Corynebacterium |
| 907 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Benzylpenicillin | NA | 0.125 | 0.125 | FALSE | NA | A.sanguinicola_A.urinae |
| 908 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Benzylpenicillin | 1 unit | 21 | 21 | FALSE | NA | A.sanguinicola_A.urinae |
| 909 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Ampicillin | NA | 0.25 | 0.25 | FALSE | NA | A.sanguinicola_A.urinae |
| 910 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Ampicillin | 2 mcg | 26 | 26 | FALSE | NA | A.sanguinicola_A.urinae |
| 911 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Amoxicillin | NA | Note | Note | FALSE | [1] Infer susceptibility from ampicillin susceptibility. | A.sanguinicola_A.urinae |
| 912 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Amoxicillin | NA | Note | Note | FALSE | [A] Infer susceptibility from ampicillin susceptibility. | A.sanguinicola_A.urinae |
| 913 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Meropenem | NA | 0.25 | 0.25 | FALSE | NA | A.sanguinicola_A.urinae |
| 914 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Meropenem | 10 mcg | 31 | 31 | FALSE | NA | A.sanguinicola_A.urinae |
| 915 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Ciprofloxacin (uncomplicated UTI only) | NA | 2 | 2 | FALSE | NA | A.sanguinicola_A.urinae |
| 916 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Ciprofloxacin (uncomplicated UTI only) | 5 mcg | 21 | 21 | FALSE | [A] Susceptibility can be inferred from norfloxacin susceptibility. See Note | A.sanguinicola_A.urinae |
| 917 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Levofloxacin (uncomplicated UTI only) | NA | 2 | 2 | FALSE | [1] Susceptibility can be inferred from ciprofloxacin susceptibility. | A.sanguinicola_A.urinae |
| 918 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Levofloxacin (uncomplicated UTI only) | 5 mcg | Note | Note | FALSE | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note | A.sanguinicola_A.urinae |
| 919 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Norfloxacin (screen) | 10 mcg | 17 | 17 | FALSE | [C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. | A.sanguinicola_A.urinae |
| 920 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Vancomycin | NA | 1 | 1 | FALSE | NA | A.sanguinicola_A.urinae |
| 921 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Vancomycin | 5 mcg | 16 | 16 | FALSE | [A] Non-wild type isolates were not available when developing the disk diffusion method. | A.sanguinicola_A.urinae |
| 922 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | A.sanguinicola_A.urinae |
| 923 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 16 | 16 | FALSE | NA | A.sanguinicola_A.urinae |
| 924 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Rifampicin | NA | 0.125 | 0.125 | FALSE | NA | A.sanguinicola_A.urinae |
| 925 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Rifampicin | 5 mcg | 25 | 25 | FALSE | NA | A.sanguinicola_A.urinae |
| 926 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Benzylpenicillin | NA | 0.03 | 0.03 | FALSE | NA | K.kingae |
| 927 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Benzylpenicillin | 1 unit | 25 | 25 | FALSE | NA | K.kingae |
| 928 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Ampicillin | NA | 0.06 | 0.06 | FALSE | [2] Susceptibility can be inferred from benzylpenicillin susceptibility. | K.kingae |
| 929 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Ampicillin | NA | Note | Note | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | K.kingae |
| 930 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Amoxicillin | NA | 0.125 | 0.125 | FALSE | [2] Susceptibility can be inferred from benzylpenicillin susceptibility. | K.kingae |
| 931 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Amoxicillin | NA | Note | Note | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | K.kingae |
| 932 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given. | K.kingae |
| 933 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given. | K.kingae |
| 934 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Cefotaxime | NA | 0.125 | 0.125 | FALSE | NA | K.kingae |
| 935 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Cefotaxime | 5 mcg | 27 | 27 | FALSE | NA | K.kingae |
| 936 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Ceftriaxone | NA | 0.06 | 0.06 | FALSE | NA | K.kingae |
| 937 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Ceftriaxone | 30 mcg | 30 | 30 | FALSE | NA | K.kingae |
| 938 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Cefuroxime iv | NA | 0.5 | 0.5 | FALSE | NA | K.kingae |
| 939 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Cefuroxime iv | 30 mcg | 29 | 29 | FALSE | NA | K.kingae |
| 940 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Meropenem | NA | 0.03 | 0.03 | FALSE | NA | K.kingae |
| 941 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Meropenem | 10 mcg | 30 | 30 | FALSE | NA | K.kingae |
| 942 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Ciprofloxacin | NA | 0.06 | 0.06 | FALSE | NA | K.kingae |
| 943 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Ciprofloxacin | 5 mcg | 28 | 28 | FALSE | NA | K.kingae |
| 944 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Levofloxacin | NA | 0.125 | 0.125 | FALSE | NA | K.kingae |
| 945 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Levofloxacin | 5 mcg | 28 | 28 | FALSE | NA | K.kingae |
| 946 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Azithromycin | NA | 0.25 | 0.25 | FALSE | [1] Susceptibility can be inferred from erythromycin susceptibility. | K.kingae |
| 947 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Azithromycin | NA | Note | Note | FALSE | [A] Infer susceptibility from erythromycin susceptibility. | K.kingae |
| 948 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Clarithromycin | NA | 0.5 | 0.5 | FALSE | [1] Susceptibility can be inferred from erythromycin susceptibility. | K.kingae |
| 949 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Infer susceptibility from erythromycin susceptibility. | K.kingae |
| 950 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Erythromycin | NA | 0.5 | 0.5 | FALSE | NA | K.kingae |
| 951 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Erythromycin | 15 mcg | 20 | 20 | FALSE | NA | K.kingae |
| 952 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Doxycycline | NA | 0.5 | 0.5 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | K.kingae |
| 953 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | K.kingae |
| 954 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Tetracycline | NA | 0.5 | 0.5 | FALSE | NA | K.kingae |
| 955 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Tetracycline | 30 mcg | 28 | 28 | FALSE | NA | K.kingae |
| 956 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Rifampicin | NA | 0.5 | 0.5 | FALSE | NA | K.kingae |
| 957 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Rifampicin | 5 mcg | 20 | 20 | FALSE | NA | K.kingae |
| 958 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Kingella kingae | NA | Trimethoprim-sulfamethoxazole | NA | 0.25 | 0.25 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | K.kingae |
| 959 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Kingella kingae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 28 | 28 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | K.kingae |
| 960 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Cefepime | NA | 1 | 4 | FALSE | NA | Aeromonas |
| 961 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Cefepime | 30 mcg | 27 | 24 | FALSE | NA | Aeromonas |
| 962 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Ceftazidime | NA | 1 | 4 | FALSE | NA | Aeromonas |
| 963 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Ceftazidime | 10 mcg | 24 | 21 | FALSE | NA | Aeromonas |
| 964 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Aztreonam | NA | 1 | 4 | FALSE | NA | Aeromonas |
| 965 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Aztreonam | 30 mcg | 29 | 26 | FALSE | NA | Aeromonas |
| 966 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Ciprofloxacin | NA | 0.25 | 0.5 | FALSE | NA | Aeromonas |
| 967 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Ciprofloxacin | 5 mcg | 27 | 24 | FALSE | NA | Aeromonas |
| 968 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Levofloxacin | NA | 0.5 | 1 | FALSE | NA | Aeromonas |
| 969 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Levofloxacin | 5 mcg | 27 | 24 | FALSE | NA | Aeromonas |
| 970 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Aeromonas |
| 971 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 19 | 16 | FALSE | [A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Aeromonas |
| 972 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Mycobacterium tuberculosis | NA | Delamanid | NA | 0.06 | 0.06 | FALSE | NA | M.tuberculosis |
| 973 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Mycobacterium tuberculosis | NA | Bedaquiline | NA | 0.25 | 0.25 | FALSE | [1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established. | M.tuberculosis |
| 974 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin | NA | 8 | 8 | FALSE | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 975 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin | 10 mcg | 14 | 14 | FALSE | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 976 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin-sulbactam | NA | 8 | 8 | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 977 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin-sulbactam | 10/10 mcg | 14 | 14 | FALSE | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 978 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin | NA | 8 | 8 | FALSE | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 979 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin | / mcg | Note | Note | FALSE | [B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 980 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | NA | 8 | 8 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 981 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | 20/10 mcg | 19 | 19 | FALSE | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review. | Enterobacterales |
| 982 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | NA | 32 | 32 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 983 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | 20/10 mcg | 16 | 16 | FALSE | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 984 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin | NA | 8 | 16 | FALSE | NA | Enterobacterales |
| 985 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin | 30 mcg | 20 | 17 | FALSE | NA | Enterobacterales |
| 986 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin-tazobactam | NA | 8 | 16 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 987 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin-tazobactam | 30/6 mcg | 20 | 17 | FALSE | NA | Enterobacterales |
| 988 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin | NA | 8 | 16 | FALSE | NA | Enterobacterales |
| 989 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin | 75 mcg | 23 | 20 | FALSE | NA | Enterobacterales |
| 990 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | NA | 8 | 16 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 991 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | 75/10 mcg | 23 | 20 | FALSE | NA | Enterobacterales |
| 992 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Temocillin | NA | Note | Note | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 993 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Temocillin | NA | Note | Note | FALSE | [C] Breakpoints still under consideration. | Enterobacterales |
| 994 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis | NA | Mecillinam oral (uncomplicated UTI only) | NA | 8 | 8 | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | Enterobacterales |
| 995 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis | NA | Mecillinam oral (uncomplicated UTI only) | 10 mcg | 15 | 15 | FALSE | [D] Ignore isolated colonies within the inhibition zone. | Enterobacterales |
| 996 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | Enterobacterales |
| 997 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | 30 mcg | 12 | 12 | FALSE | NA | Enterobacterales |
| 998 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | Enterobacterales |
| 999 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | 30 mcg | 14 | 14 | FALSE | NA | Enterobacterales |
| 1000 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli, and Klebsiella spp. (except K. aerogenes) | NA | Cefazolin (infections originating from the urinary tract) | NA | 0.001 | 4 | FALSE | NA | Enterobacterales |
| 1001 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli, and Klebsiella spp. (except K. aerogenes) | NA | Cefazolin (infections originating from the urinary tract) | IP mcg | IP | IP | FALSE | NA | Enterobacterales |
| 1002 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefepime | NA | 1 | 4 | FALSE | NA | Enterobacterales |
| 1003 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefepime | 30 mcg | 27 | 24 | FALSE | NA | Enterobacterales |
| 1004 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | NA | 1 | 1 | FALSE | NA | Enterobacterales |
| 1005 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | 5 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 1006 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefotaxime | NA | 1 | 2 | FALSE | NA | Enterobacterales |
| 1007 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefotaxime | 5 mcg | 20 | 17 | FALSE | NA | Enterobacterales |
| 1008 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefoxitin (screen only) | 30 mcg | 19 | 19 | FALSE | [2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type. | Enterobacterales |
| 1009 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | NA | 1 | 1 | FALSE | NA | Enterobacterales |
| 1010 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | 10 mcg | 21 | 21 | FALSE | NA | Enterobacterales |
| 1011 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftaroline | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 1012 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftaroline | 5 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 1013 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime | NA | 1 | 4 | FALSE | NA | Enterobacterales |
| 1014 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime | 10 mcg | 22 | 19 | FALSE | NA | Enterobacterales |
| 1015 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime-avibactam | NA | 8 | 8 | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 1016 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime-avibactam | 10/4 mcg | 13 | 13 | FALSE | NA | Enterobacterales |
| 1017 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftibuten (infections originating from the urinary tract) | NA | 1 | 1 | FALSE | NA | Enterobacterales |
| 1018 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftibuten (infections originating from the urinary tract) | 30 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 1019 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftobiprole | NA | 0.25 | 0.25 | FALSE | NA | Enterobacterales |
| 1020 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftobiprole | 5 mcg | 23 | 23 | FALSE | NA | Enterobacterales |
| 1021 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftolozane-tazobactam | NA | 2 | 2 | FALSE | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications. | Enterobacterales |
| 1022 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftolozane-tazobactam | 30/10 mcg | 22 | 22 | FALSE | [4] See table of dosages for dosing for different indications. | Enterobacterales |
| 1023 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftriaxone | NA | 1 | 2 | FALSE | NA | Enterobacterales |
| 1024 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftriaxone | 30 mcg | 25 | 22 | FALSE | NA | Enterobacterales |
| 1025 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime iv | NA | 0.001 | 8 | FALSE | NA | Enterobacterales |
| 1026 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime iv | 30 mcg | 50 | 19 | FALSE | NA | Enterobacterales |
| 1027 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime oral (uncomplicated UTI only) | NA | 8 | 8 | FALSE | NA | Enterobacterales |
| 1028 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | NA | Cefuroxime oral (uncomplicated UTI only) | 30 mcg | 19 | 19 | FALSE | NA | Enterobacterales |
| 1029 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 1030 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ertapenem | 10 mcg | 25 | 25 | FALSE | NA | Enterobacterales |
| 1031 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem | NA | 2 | 4 | FALSE | NA | Enterobacterales |
| 1032 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem | 10 mcg | 22 | 17 | FALSE | NA | Enterobacterales |
| 1033 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Morganella morganii,Proteus spp. and Providencia spp. | NA | Imipenem | NA | 0.001 | 4 | FALSE | [2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem. | Enterobacterales |
| 1034 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Morganella morganii,Proteus spp. and Providencia spp. | NA | Imipenem | 10 mcg | 50 | 17 | FALSE | [2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem. | Enterobacterales |
| 1035 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales except Morganella spp. | NA | Imipenem-relebactam | NA | 2 | 2 | FALSE | [3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Enterobacterales |
| 1036 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales except Morganella spp. | NA | Imipenem-relebactam | IP mcg | IP | IP | FALSE | NA | Enterobacterales |
| 1037 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Enterobacterales |
| 1038 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem | 10 mcg | 22 | 16 | FALSE | NA | Enterobacterales |
| 1039 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem-vaborbactam | NA | 8 | 8 | FALSE | [4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 1040 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem-vaborbactam | IP mcg | IP | IP | FALSE | NA | Enterobacterales |
| 1041 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Aztreonam | NA | 1 | 4 | FALSE | [1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes. | Enterobacterales |
| 1042 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Aztreonam | 30 mcg | 26 | 21 | FALSE | [1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes. | Enterobacterales |
| 1043 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ciprofloxacin | NA | 0.25 | 0.5 | FALSE | NA | Enterobacterales |
| 1044 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ciprofloxacin | 5 mcg | 25 | 22 | FALSE | NA | Enterobacterales |
| 1045 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Salmonella spp. | NA | Ciprofloxacin | NA | 0.06 | 0.06 | FALSE | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 1046 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Salmonella spp. | NA | Ciprofloxacin | NA | Note | Note | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 1047 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Salmonella spp. | NA | Pefloxacin (screen only) | 5 mcg | 24 | 24 | FALSE | [2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 1048 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli | NA | Delafloxacin | NA | 0.125 | 0.125 | FALSE | NA | Enterobacterales |
| 1049 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli | NA | Delafloxacin | NA | Note | Note | FALSE | [D] A disk diffusion test is not yet developed. Perform an MIC test. | Enterobacterales |
| 1050 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Levofloxacin | NA | 0.5 | 1 | FALSE | NA | Enterobacterales |
| 1051 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Levofloxacin | 5 mcg | 23 | 19 | FALSE | NA | Enterobacterales |
| 1052 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Moxifloxacin | NA | 0.25 | 0.25 | FALSE | NA | Enterobacterales |
| 1053 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Moxifloxacin | 5 mcg | 22 | 22 | FALSE | NA | Enterobacterales |
| 1054 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 1055 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | 10 mcg | 22 | 22 | FALSE | NA | Enterobacterales |
| 1056 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ofloxacin | NA | 0.25 | 0.5 | FALSE | NA | Enterobacterales |
| 1057 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ofloxacin | 5 mcg | 24 | 22 | FALSE | NA | Enterobacterales |
| 1058 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amikacin (systemic infections) | NA | (8) | (8) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1059 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amikacin (systemic infections) | 30 mcg | (18) | (18) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1060 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amikacin (infections originating from the urinary tract) | NA | 8 | 8 | FALSE | NA | Enterobacterales |
| 1061 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amikacin (infections originating from the urinary tract) | 30 mcg | 18 | 18 | FALSE | NA | Enterobacterales |
| 1062 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Gentamicin (systemic infections) | NA | (2) | (2) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1063 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Gentamicin (systemic infections) | 10 mcg | (17) | (17) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1064 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Gentamicin (infections originating from the urinary tract) | NA | 2 | 2 | FALSE | NA | Enterobacterales |
| 1065 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Gentamicin (infections originating from the urinary tract) | 10 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 1066 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Netilmicin | NA | IE | IE | FALSE | NA | Enterobacterales |
| 1067 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Netilmicin | NA | IE | IE | FALSE | NA | Enterobacterales |
| 1068 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Tobramycin (systemic infections) | NA | (2) | (2) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1069 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Tobramycin (systemic infections) | 10 mcg | (17) | (17) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1070 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Tobramycin (infections originating from the urinary tract) | NA | 2 | 2 | FALSE | NA | Enterobacterales |
| 1071 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Tobramycin (infections originating from the urinary tract) | 10 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 1072 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli | NA | Eravacycline | NA | 0.5 | 0.5 | FALSE | NA | Enterobacterales |
| 1073 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli | NA | Eravacycline | 20 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 1074 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli and C. koseri | NA | Tigecycline | NA | 0.5 | 0.5 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1075 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli and C. koseri | NA | Tigecycline | 15 mcg | 18 | 18 | FALSE | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method. | Enterobacterales |
| 1076 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | Enterobacterales |
| 1077 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Chloramphenicol | 30 mcg | 17 | 17 | FALSE | NA | Enterobacterales |
| 1078 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Colistin | NA | 2 | 2 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Enterobacterales |
| 1079 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Colistin | NA | Note | Note | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Enterobacterales |
| 1080 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin iv | NA | 32 | 32 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Enterobacterales |
| 1081 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin iv | 200 mcg | 24 | 24 | FALSE | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 1082 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | NA | 32 | 32 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Enterobacterales |
| 1083 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | 200 mcg | 24 | 24 | FALSE | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 1084 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | FALSE | NA | Enterobacterales |
| 1085 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 11 | 11 | FALSE | NA | Enterobacterales |
| 1086 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. coli | NA | Nitroxoline (uncomplicated UTI only) | NA | 16 | 16 | FALSE | NA | Enterobacterales |
| 1087 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. coli | NA | Nitroxoline (uncomplicated UTI only) | 30 mcg | 15 | 15 | FALSE | NA | Enterobacterales |
| 1088 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | NA | 4 | 4 | FALSE | NA | Enterobacterales |
| 1089 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | 15 | 15 | FALSE | NA | Enterobacterales |
| 1090 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | FALSE | [3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterobacterales |
| 1091 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 14 | 11 | FALSE | [3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterobacterales |
| 1092 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin | NA | 0.001 | 16 | FALSE | NA | Pseudomonas |
| 1093 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin | 30 mcg | 50 | 18 | FALSE | NA | Pseudomonas |
| 1094 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | NA | 0.001 | 16 | FALSE | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 1095 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | 30/6 mcg | 50 | 18 | FALSE | NA | Pseudomonas |
| 1096 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin | NA | 0.001 | 16 | FALSE | NA | Pseudomonas |
| 1097 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin | 75 mcg | 50 | 18 | FALSE | NA | Pseudomonas |
| 1098 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | NA | 0.001 | 16 | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Pseudomonas |
| 1099 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | 75/10 mcg | 50 | 18 | FALSE | NA | Pseudomonas |
| 1100 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Cefepime | NA | 0.001 | 8 | FALSE | NA | Pseudomonas |
| 1101 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Cefepime | 30 mcg | 50 | 21 | FALSE | NA | Pseudomonas |
| 1102 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftazidime | NA | 0.001 | 8 | FALSE | NA | Pseudomonas |
| 1103 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftazidime | 10 mcg | 50 | 17 | FALSE | NA | Pseudomonas |
| 1104 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | P. aeruginosa | NA | Ceftazidime-avibactam | NA | 8 | 8 | FALSE | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 1105 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | P. aeruginosa | NA | Ceftazidime-avibactam | 10/4 mcg | 17 | 17 | FALSE | NA | Pseudomonas |
| 1106 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1107 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1108 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | P. aeruginosa | NA | Ceftolozane-tazobactam | NA | 4 | 4 | FALSE | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications. | Pseudomonas |
| 1109 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | P. aeruginosa | NA | Ceftolozane-tazobactam | 30/10 mcg | 24 | 24 | FALSE | [2] See table of dosages for dosing for different indications. | Pseudomonas |
| 1110 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Imipenem | NA | 0.001 | 4 | FALSE | NA | Pseudomonas |
| 1111 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Imipenem | 10 mcg | 50 | 20 | FALSE | NA | Pseudomonas |
| 1112 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | P. aeruginosa | NA | Imipenem-relebactam | NA | 2 | 2 | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Pseudomonas |
| 1113 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | P. aeruginosa | NA | Imipenem-relebactam | IP mcg | IP | IP | FALSE | NA | Pseudomonas |
| 1114 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Pseudomonas |
| 1115 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Meropenem | 10 mcg | 24 | 18 | FALSE | NA | Pseudomonas |
| 1116 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | P. aeruginosa | NA | Meropenem-vaborbactam | NA | 8 | 8 | FALSE | [2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 1117 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | P. aeruginosa | NA | Meropenem-vaborbactam | IP mcg | IP | IP | FALSE | NA | Pseudomonas |
| 1118 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Aztreonam | NA | 0.001 | 16 | FALSE | NA | Pseudomonas |
| 1119 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Aztreonam | 30 mcg | 50 | 18 | FALSE | NA | Pseudomonas |
| 1120 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ciprofloxacin | NA | 0.001 | 0.5 | FALSE | NA | Pseudomonas |
| 1121 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ciprofloxacin | 5 mcg | 50 | 26 | FALSE | NA | Pseudomonas |
| 1122 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Delafloxacin | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1123 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Delafloxacin | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1124 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Levofloxacin | NA | 0.001 | 1 | FALSE | NA | Pseudomonas |
| 1125 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Levofloxacin | 5 mcg | 50 | 22 | FALSE | NA | Pseudomonas |
| 1126 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Amikacin (systemic infections) | NA | (16) | (16) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1127 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Amikacin (systemic infections) | 30 mcg | (15) | (15) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1128 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Amikacin (infections originating from the urinary tract) | NA | 16 | 16 | FALSE | NA | Pseudomonas |
| 1129 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Amikacin (infections originating from the urinary tract) | 30 mcg | 15 | 15 | FALSE | NA | Pseudomonas |
| 1130 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Gentamicin (systemic infections) | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1131 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Gentamicin (systemic infections) | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1132 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Gentamicin (infections originating from the urinary tract) | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1133 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Gentamicin (infections originating from the urinary tract) | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1134 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Netilmicin | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1135 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Netilmicin | NA | IE | IE | FALSE | NA | Pseudomonas |
| 1136 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Tobramycin (systemic infections) | NA | (2) | (2) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1137 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Tobramycin (systemic infections) | 10 mcg | (18) | (18) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1138 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Tobramycin (infections originating from the urinary tract) | NA | 2 | 2 | FALSE | NA | Pseudomonas |
| 1139 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Tobramycin (infections originating from the urinary tract) | 10 mcg | 18 | 18 | FALSE | NA | Pseudomonas |
| 1140 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Colistin | NA | 2 | 2 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Pseudomonas |
| 1141 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Colistin | NA | Note | Note | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Pseudomonas |
| 1142 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | NA | 0.001 | 4 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.maltophilia |
| 1143 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 50 | 16 | FALSE | [A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.maltophilia |
| 1144 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1145 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1146 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1147 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1148 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1149 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1150 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1151 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1152 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1153 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1154 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Imipenem | NA | 2 | 4 | FALSE | NA | Acinetobacter |
| 1155 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Imipenem | 10 mcg | 24 | 21 | FALSE | NA | Acinetobacter |
| 1156 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Imipenem-relebactam | NA | 2 | 2 | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Acinetobacter |
| 1157 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Imipenem-relebactam | IP mcg | IP | IP | FALSE | NA | Acinetobacter |
| 1158 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem | NA | 2 | 8 | FALSE | NA | Acinetobacter |
| 1159 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem | 10 mcg | 21 | 15 | FALSE | NA | Acinetobacter |
| 1160 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1161 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1162 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ciprofloxacin | NA | 0.001 | 1 | FALSE | NA | Acinetobacter |
| 1163 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ciprofloxacin | 5 mcg | 50 | 21 | FALSE | NA | Acinetobacter |
| 1164 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Delafloxacin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1165 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Delafloxacin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1166 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Levofloxacin | NA | 0.5 | 1 | FALSE | NA | Acinetobacter |
| 1167 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Levofloxacin | 5 mcg | 23 | 20 | FALSE | NA | Acinetobacter |
| 1168 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Amikacin (systemic infections) | NA | (8) | (8) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1169 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Amikacin (systemic infections) | 30 mcg | (19) | (19) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1170 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Amikacin (infections originating from the urinary tract) | NA | 8 | 8 | FALSE | NA | Acinetobacter |
| 1171 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Amikacin (infections originating from the urinary tract) | 30 mcg | 19 | 19 | FALSE | NA | Acinetobacter |
| 1172 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Gentamicin (systemic infections) | NA | (4) | (4) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1173 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Gentamicin (systemic infections) | 10 mcg | (17) | (17) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1174 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Gentamicin (infections originating from the urinary tract) | NA | 4 | 4 | FALSE | NA | Acinetobacter |
| 1175 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Gentamicin (infections originating from the urinary tract) | 10 mcg | 17 | 17 | FALSE | NA | Acinetobacter |
| 1176 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Netilmicin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1177 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Netilmicin | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1178 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tobramycin (systemic infections) | NA | (4) | (4) | TRUE | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1179 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tobramycin (systemic infections) | 10 mcg | (17) | (17) | TRUE | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1180 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tobramycin (infections originating from the urinary tract) | NA | 4 | 4 | FALSE | NA | Acinetobacter |
| 1181 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tobramycin (infections originating from the urinary tract) | 10 mcg | 17 | 17 | FALSE | NA | Acinetobacter |
| 1182 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Eravacycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1183 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Eravacycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1184 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Minocycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1185 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Minocycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1186 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tigecycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1187 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tigecycline | NA | IE | IE | FALSE | NA | Acinetobacter |
| 1188 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Colistin | NA | 2 | 2 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Acinetobacter |
| 1189 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Colistin | NA | Note | Note | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Acinetobacter |
| 1190 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Acinetobacter |
| 1191 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 14 | 11 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Acinetobacter |
| 1192 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ampicillin | NA | 4 | 8 | FALSE | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1193 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ampicillin | 2 mcg | 10 | 8 | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1194 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ampicillin-sulbactam | NA | 4 | 8 | FALSE | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1195 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1196 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amoxicillin | NA | 4 | 8 | FALSE | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1197 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amoxicillin | NA | Note | Note | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1198 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | NA | 4 | 8 | FALSE | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1199 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only. | Enterococcus |
| 1200 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Piperacillin | NA | Note | Note | FALSE | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | Enterococcus |
| 1201 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Piperacillin | NA | Note | Note | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | Enterococcus |
| 1202 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | Enterococcus |
| 1203 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | Enterococcus |
| 1204 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Imipenem | NA | 0.001 | 4 | FALSE | NA | Enterococcus |
| 1205 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Imipenem | 10 mcg | 50 | 21 | FALSE | NA | Enterococcus |
| 1206 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Imipenem-relebactam | NA | IE | IE | FALSE | NA | Enterococcus |
| 1207 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Imipenem-relebactam | NA | IE | IE | FALSE | NA | Enterococcus |
| 1208 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 1209 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | 5 mcg | 15 | 15 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 1210 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Delafloxacin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1211 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Delafloxacin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1212 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 1213 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | 5 mcg | 15 | 15 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 1214 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Norfloxacin (screen only) | 10 mcg | 12 | 12 | FALSE | [B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. | Enterococcus |
| 1215 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amikacin | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1216 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amikacin | NA | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1217 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1218 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | 30 mcg | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1219 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Netilmicin | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1220 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Netilmicin | NA | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1221 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | NA | Note | Note | FALSE | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1222 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | 300 mcg | Note | Note | FALSE | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1223 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tobramycin | NA | Note | Note | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1224 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tobramycin | NA | Note | Note | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 1225 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Dalbavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1226 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Dalbavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1227 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Oritavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1228 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Oritavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1229 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Teicoplanin | NA | 2 | 2 | FALSE | NA | Enterococcus |
| 1230 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Teicoplanin | 30 mcg | 16 | 16 | FALSE | NA | Enterococcus |
| 1231 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Telavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1232 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Telavancin | NA | IE | IE | FALSE | NA | Enterococcus |
| 1233 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Vancomycin | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 1234 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Vancomycin | 5 mcg | 12 | 12 | FALSE | [A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation. | Enterococcus |
| 1235 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. faecium | NA | Quinupristin-dalfopristin | NA | 1 | 4 | FALSE | NA | Enterococcus |
| 1236 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. faecium | NA | Quinupristin-dalfopristin | 15 mcg | 22 | 20 | FALSE | NA | Enterococcus |
| 1237 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. faecalis | NA | Eravacycline | NA | 0.125 | 0.125 | FALSE | NA | Enterococcus |
| 1238 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. faecalis | NA | Eravacycline | 20 mcg | 22 | 22 | FALSE | NA | Enterococcus |
| 1239 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. faecium | NA | Eravacycline | NA | 0.125 | 0.125 | FALSE | NA | Enterococcus |
| 1240 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. faecium | NA | Eravacycline | 20 mcg | 24 | 24 | FALSE | NA | Enterococcus |
| 1241 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. faecalis | NA | Tigecycline | NA | 0.25 | 0.25 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 1242 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. faecalis | NA | Tigecycline | 15 mcg | 20 | 20 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 1243 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. faecium | NA | Tigecycline | NA | 0.25 | 0.25 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 1244 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. faecium | NA | Tigecycline | 15 mcg | 22 | 22 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 1245 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Linezolid | NA | 4 | 4 | FALSE | NA | Enterococcus |
| 1246 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Linezolid | 10 mcg | 20 | 20 | FALSE | NA | Enterococcus |
| 1247 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tedizolid | NA | IE | IE | FALSE | NA | Enterococcus |
| 1248 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tedizolid | NA | IE | IE | FALSE | NA | Enterococcus |
| 1249 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Daptomycin | NA | IE | IE | FALSE | [1] For more information, see http://www.eucast.org/guidance_documents/. | Enterococcus |
| 1250 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Daptomycin | NA | IE | IE | FALSE | [1] For more information, see http://www.eucast.org/guidance_documents/. | Enterococcus |
| 1251 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | E. faecalis | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | FALSE | NA | Enterococcus |
| 1252 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | E. faecalis | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 15 | 15 | FALSE | NA | Enterococcus |
| 1253 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | FALSE | NA | Enterococcus |
| 1254 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | FALSE | NA | Enterococcus |
| 1255 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | Note | Note | FALSE | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 1256 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | Note | Note | FALSE | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 1257 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | NA | Note | Note | FALSE | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterococcus |
| 1258 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | Note | Note | FALSE | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterococcus |
| 1259 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | NA | 0.25 | 0.25 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1260 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | 1 unit | 18 | 18 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1261 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ampicillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1262 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ampicillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1263 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1264 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1265 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1266 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1267 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1268 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1269 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Piperacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1270 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Piperacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1271 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1272 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1273 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1274 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1275 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Oxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1276 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Oxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1277 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Cloxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1278 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Cloxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1279 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Dicloxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1280 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Dicloxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1281 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, C and G | NA | Flucloxacillin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1282 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, C and G | NA | Flucloxacillin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 1283 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefaclor | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1284 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefaclor | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1285 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefadroxil | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1286 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefadroxil | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1287 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefalexin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1288 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefalexin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1289 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefazolin | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1290 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefazolin | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1291 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefepime | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1292 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefepime | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1293 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefotaxime | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1294 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefotaxime | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1295 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefpodoxime | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1296 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefpodoxime | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1297 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftaroline | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1298 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftaroline | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1299 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftibuten | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1300 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftibuten | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1301 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1302 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1303 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1304 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1305 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftriaxone | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1306 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftriaxone | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1307 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1308 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1309 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1310 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1311 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ertapenem | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1312 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ertapenem | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1313 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Imipenem | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1314 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Imipenem | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1315 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Imipenem-relebactam | NA | Note | Note | FALSE | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1316 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Imipenem-relebactam | NA | Note | Note | FALSE | [2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1317 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Meropenem | NA | Note | Note | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1318 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Meropenem | NA | Note | Note | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 1319 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | NA | Note | Note | FALSE | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1320 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | NA | Note | Note | FALSE | [2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 1321 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Delafloxacin | NA | 0.03 | 0.03 | FALSE | NA | Streptococcus A,B,C,G |
| 1322 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Delafloxacin | NA | Note | Note | FALSE | [A] A disk diffusion test is not yet developed. Perform an MIC test. | Streptococcus A,B,C,G |
| 1323 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Levofloxacin | NA | 0.001 | 2 | FALSE | NA | Streptococcus A,B,C,G |
| 1324 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Levofloxacin | 5 mcg | 50 | 17 | FALSE | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 1325 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Moxifloxacin | NA | 0.5 | 0.5 | FALSE | NA | Streptococcus A,B,C,G |
| 1326 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Moxifloxacin | 5 mcg | 19 | 19 | FALSE | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 1327 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Norfloxacin (screen only) | 10 mcg | 12 | Note | FALSE | [C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as "susceptible increased exposure" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Streptococcus A,B,C,G |
| 1328 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Dalbavancin | NA | 0.125 | 0.125 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1329 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Dalbavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1330 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Oritavancin | NA | 0.25 | 0.25 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1331 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Oritavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1332 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Teicoplanin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1333 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Teicoplanin | 30 mcg | 15 | 15 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1334 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Telavancin | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1335 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Telavancin | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1336 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1337 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Vancomycin | 5 mcg | 13 | 13 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1338 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Azithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1339 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Azithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1340 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Clarithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1341 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1342 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Erythromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1343 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Erythromycin | 15 mcg | 21 | 18 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1344 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Roxithromycin | NA | 0.5 | 1 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1345 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 1346 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Telithromycin | NA | 0.25 | 0.5 | FALSE | NA | Streptococcus A,B,C,G |
| 1347 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Telithromycin | 15 mcg | 20 | 17 | FALSE | NA | Streptococcus A,B,C,G |
| 1348 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known. | Streptococcus A,B,C,G |
| 1349 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Clindamycin | 2 mcg | 17 | 17 | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known. | Streptococcus A,B,C,G |
| 1350 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 1351 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 1352 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Eravacycline | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1353 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Eravacycline | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1354 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Minocycline | NA | 0.5 | 0.5 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 1355 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Minocycline | 30 mcg | 23 | 23 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 1356 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 1357 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tetracycline | 30 mcg | 23 | 20 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 1358 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tigecycline | NA | 0.125 | 0.125 | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1359 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tigecycline | 15 mcg | 19 | 19 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1360 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Linezolid | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1361 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Linezolid | 10 mcg | 19 | 19 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1362 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tedizolid | NA | 0.5 | 0.5 | FALSE | [2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1363 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tedizolid | 2 mcg | 18 | 18 | FALSE | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1364 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | Streptococcus A,B,C,G |
| 1365 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Chloramphenicol | 30 mcg | 19 | 19 | FALSE | NA | Streptococcus A,B,C,G |
| 1366 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Daptomycin | NA | 1 | 1 | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1367 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Daptomycin | NA | Note | Note | FALSE | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 1368 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Fusidic acid | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1369 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Fusidic acid | NA | IE | IE | FALSE | NA | Streptococcus A,B,C,G |
| 1370 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. agalactiae (group B streptococci) | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | FALSE | NA | Streptococcus A,B,C,G |
| 1371 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. agalactiae (group B streptococci) | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 15 | 15 | FALSE | NA | Streptococcus A,B,C,G |
| 1372 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Rifampicin | NA | 0.06 | 0.5 | FALSE | NA | Streptococcus A,B,C,G |
| 1373 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Rifampicin | 5 mcg | 21 | 15 | FALSE | NA | Streptococcus A,B,C,G |
| 1374 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. agalactiae (group B streptococci) | NA | Trimethoprim (uncomplicated UTI only) | NA | 2 | 2 | FALSE | NA | Streptococcus A,B,C,G |
| 1375 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. agalactiae (group B streptococci) | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | IP | IP | FALSE | NA | Streptococcus A,B,C,G |
| 1376 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | NA | 1 | 2 | FALSE | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Streptococcus A,B,C,G |
| 1377 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 18 | 15 | FALSE | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Streptococcus A,B,C,G |
| 1378 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | NA | 0.06 | 2 | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages. | S.pneumoniae |
| 1379 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages. | S.pneumoniae |
| 1380 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | NA | 0.06 | 0.06 | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1381 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1382 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ampicillin | NA | 0.5 | 2 | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1383 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ampicillin | 2 mcg | 22 | 16 | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1384 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1385 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1386 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin iv | NA | Note | Note | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1387 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin iv | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1388 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin oral | NA | 0.5 | 1 | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1389 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin oral | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 1390 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | NA | Note | Note | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1391 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1392 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | NA | 0.5 | 1 | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1393 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1394 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Piperacillin | NA | Note | Note | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1395 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Piperacillin | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1396 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1397 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1398 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1399 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1400 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Oxacillin (screen only) | 1 mcg | 20 | Note | FALSE | [D] For interpretation of the oxacillin disk screen, see flow chart below. | S.pneumoniae |
| 1401 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefaclor | NA | 0.001 | 0.5 | FALSE | NA | S.pneumoniae |
| 1402 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefaclor | 30 mcg | 50 | 28 | FALSE | NA | S.pneumoniae |
| 1403 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefepime | NA | 1 | 2 | FALSE | NA | S.pneumoniae |
| 1404 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefepime | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1405 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefotaxime | NA | 0.5 | 2 | FALSE | NA | S.pneumoniae |
| 1406 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefotaxime | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1407 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefpodoxime | NA | 0.25 | 0.5 | FALSE | NA | S.pneumoniae |
| 1408 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefpodoxime | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1409 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftaroline | NA | 0.25 | 0.25 | FALSE | NA | S.pneumoniae |
| 1410 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftaroline | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1411 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftobiprole | NA | 0.5 | 0.5 | FALSE | NA | S.pneumoniae |
| 1412 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftobiprole | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1413 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftriaxone | NA | 0.5 | 2 | FALSE | NA | S.pneumoniae |
| 1414 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftriaxone | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1415 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefuroxime iv | NA | 0.5 | 1 | FALSE | NA | S.pneumoniae |
| 1416 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefuroxime iv | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1417 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefuroxime oral | NA | 0.25 | 0.5 | FALSE | NA | S.pneumoniae |
| 1418 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefuroxime oral | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1419 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | S.pneumoniae |
| 1420 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ertapenem | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1421 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Imipenem | NA | 2 | 2 | FALSE | NA | S.pneumoniae |
| 1422 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Imipenem | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1423 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Imipenem-relebactam | NA | Note | Note | FALSE | [3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1424 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Imipenem-relebactam | NA | Note | Note | FALSE | [3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1425 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | NA | 2 | 2 | FALSE | NA | S.pneumoniae |
| 1426 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | S.pneumoniae |
| 1427 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | FALSE | NA | S.pneumoniae |
| 1428 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem(meningitis) | NA | Note | Note | FALSE | [A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC. | S.pneumoniae |
| 1429 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | NA | Note | Note | FALSE | [3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1430 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | NA | Note | Note | FALSE | [3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | S.pneumoniae |
| 1431 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Delafloxacin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1432 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Delafloxacin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1433 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Levofloxacin | NA | 0.001 | 2 | FALSE | NA | S.pneumoniae |
| 1434 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Levofloxacin | 5 mcg | 50 | 16 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 1435 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Moxifloxacin | NA | 0.5 | 0.5 | FALSE | NA | S.pneumoniae |
| 1436 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Moxifloxacin | 5 mcg | 22 | 22 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 1437 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Norfloxacin (screen only) | 10 mcg | 10 | Note | FALSE | [B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as "susceptible increased exposure" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | S.pneumoniae |
| 1438 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Dalbavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1439 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Dalbavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1440 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Oritavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1441 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Oritavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1442 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Teicoplanin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1443 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Teicoplanin | 30 mcg | 17 | 17 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1444 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Telavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1445 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Telavancin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1446 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1447 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Vancomycin | 5 mcg | 16 | 16 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1448 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Azithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1449 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Azithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1450 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Clarithromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1451 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1452 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Erythromycin | NA | 0.25 | 0.5 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1453 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Erythromycin | 15 mcg | 22 | 19 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1454 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Roxithromycin | NA | 0.5 | 1 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1455 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1456 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Telithromycin | NA | 0.25 | 0.5 | FALSE | NA | S.pneumoniae |
| 1457 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Telithromycin | 15 mcg | 23 | 20 | FALSE | NA | S.pneumoniae |
| 1458 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | S.pneumoniae |
| 1459 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Clindamycin | 2 mcg | 19 | 19 | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | S.pneumoniae |
| 1460 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1461 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1462 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Eravacycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1463 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Eravacycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1464 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Minocycline | NA | 0.5 | 0.5 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1465 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Minocycline | 30 mcg | 24 | 24 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1466 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1467 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tetracycline | 30 mcg | 25 | 22 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1468 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tigecycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1469 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tigecycline | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1470 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Linezolid | NA | 2 | 2 | FALSE | NA | S.pneumoniae |
| 1471 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Linezolid | 10 mcg | 22 | 22 | FALSE | NA | S.pneumoniae |
| 1472 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tedizolid | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1473 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tedizolid | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1474 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Chloramphenicol | NA | 8 | 8 | FALSE | NA | S.pneumoniae |
| 1475 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Chloramphenicol | 30 mcg | 21 | 21 | FALSE | NA | S.pneumoniae |
| 1476 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Daptomycin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1477 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Daptomycin | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1478 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1479 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | S.pneumoniae |
| 1480 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Rifampicin | NA | 0.125 | 0.5 | FALSE | NA | S.pneumoniae |
| 1481 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Rifampicin | 5 mcg | 22 | 17 | FALSE | NA | S.pneumoniae |
| 1482 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | NA | 1 | 2 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.pneumoniae |
| 1483 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 13 | 10 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.pneumoniae |
| 1484 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Benzylpenicillin | NA | 0.25 | 2 | FALSE | NA | Viridans group streptococci |
| 1485 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Benzylpenicillin | 1 unit | 18 | 12 | FALSE | NA | Viridans group streptococci |
| 1486 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Benzylpenicillin (screen only) | 1 unit | 18 | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 1487 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ampicillin | NA | 0.5 | 2 | FALSE | NA | Viridans group streptococci |
| 1488 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ampicillin | 2 mcg | 21 | 15 | FALSE | NA | Viridans group streptococci |
| 1489 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1490 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1491 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amoxicillin | NA | 0.5 | 2 | FALSE | NA | Viridans group streptococci |
| 1492 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Amoxicillin | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1493 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1494 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1495 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Piperacillin | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1496 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Piperacillin | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1497 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1498 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1499 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1500 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ticarcillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1501 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1502 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1503 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1504 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1505 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefazolin | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 1506 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefazolin | 30 mcg | IP | IP | FALSE | NA | Viridans group streptococci |
| 1507 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefepime | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 1508 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefepime | 30 mcg | 25 | 25 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1509 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefotaxime | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 1510 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefotaxime | 5 mcg | 23 | 23 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1511 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. anginosus group | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1512 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. anginosus group | NA | Ceftolozane-tazobactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1513 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ceftriaxone | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 1514 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ceftriaxone | 30 mcg | 27 | 27 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1515 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefuroxime iv | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 1516 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefuroxime iv | 30 mcg | 26 | 26 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1517 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | Viridans group streptococci |
| 1518 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ertapenem | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1519 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Imipenem | NA | 2 | 2 | FALSE | NA | Viridans group streptococci |
| 1520 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Imipenem | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1521 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Imipenem-relebactam | NA | 2 | 2 | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Viridans group streptococci |
| 1522 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Imipenem-relebactam | IP mcg | IP | IP | FALSE | NA | Viridans group streptococci |
| 1523 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Meropenem | NA | 2 | 2 | FALSE | NA | Viridans group streptococci |
| 1524 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Meropenem | NA | Note | Note | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1525 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1526 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1527 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. anginosus group | NA | Delafloxacin | NA | 0.03 | 0.03 | FALSE | NA | Viridans group streptococci |
| 1528 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. anginosus group | NA | Delafloxacin | NA | Note | Note | FALSE | [A] A disk diffusion test is not yet developed. Perform an MIC test. | Viridans group streptococci |
| 1529 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Levofloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1530 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Levofloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1531 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1532 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Moxifloxacin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1533 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amikacin | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 1534 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 1535 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Netilmicin | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 1536 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tobramycin | NA | Note | Note | FALSE | NA | Viridans group streptococci |
| 1537 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. anginosus group | NA | Dalbavancin | NA | 0.125 | 0.125 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1538 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. anginosus group | NA | Dalbavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1539 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. anginosus group | NA | Oritavancin | NA | 0.25 | 0.25 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1540 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. anginosus group | NA | Oritavancin | NA | Note | Note | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1541 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Teicoplanin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1542 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Teicoplanin | 30 mcg | 16 | 16 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1543 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Telavancin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1544 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Telavancin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1545 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Vancomycin | NA | 2 | 2 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1546 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Vancomycin | 5 mcg | 15 | 15 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1547 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Azithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1548 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Azithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1549 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Clarithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1550 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Clarithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1551 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Erythromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1552 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Erythromycin | 15 mcg | IE | IE | FALSE | NA | Viridans group streptococci |
| 1553 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Roxithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1554 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Roxithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1555 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Telithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1556 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Telithromycin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1557 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Clindamycin | NA | 0.5 | 0.5 | FALSE | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | Viridans group streptococci |
| 1558 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Clindamycin | 2 mcg | 19 | 19 | FALSE | [A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | Viridans group streptococci |
| 1559 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Quinupristin-dalfopristin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1560 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Quinupristin-dalfopristin | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1561 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Eravacycline | NA | 0.125 | 0.125 | FALSE | NA | Viridans group streptococci |
| 1562 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Eravacycline | 20 mcg | 17 | 17 | FALSE | NA | Viridans group streptococci |
| 1563 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tigecycline | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1564 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Viridans group streptococci | NA | Tigecycline | NA | IE | IE | FALSE | NA | Viridans group streptococci |
| 1565 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | S. anginosus group | NA | Tedizolid | NA | 0.25 | 0.25 | FALSE | NA | Viridans group streptococci |
| 1566 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | S. anginosus group | NA | Tedizolid | 2 mcg | 18 | 18 | FALSE | NA | Viridans group streptococci |
| 1567 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Benzylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1568 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Benzylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1569 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Benzylpenicillin (screen only) | 1 unit | 12 | Note | FALSE | [1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1570 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ampicillin | NA | 1 | 1 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1571 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ampicillin | 2 mcg | 18 | 18 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1572 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ampicillin-sulbactam | NA | 1 | 1 | FALSE | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid. | H.influenzae |
| 1573 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ampicillin-sulbactam | 10/10 mcg | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | H.influenzae |
| 1574 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin iv | NA | 2 | 2 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1575 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin iv | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1576 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin oral | NA | 0.001 | 2 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1577 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin oral | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1578 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | NA | 2 | 2 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | H.influenzae |
| 1579 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | 2/1 mcg | 15 | 15 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1580 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | NA | 0.001 | 2 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | H.influenzae |
| 1581 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | 2/1 mcg | 50 | 15 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1582 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Piperacillin | NA | IE | IE | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1583 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Piperacillin | NA | IE | IE | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1584 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Piperacillin-tazobactam | NA | 0.25 | 0.25 | FALSE | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | H.influenzae |
| 1585 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Piperacillin-tazobactam | 30/6 mcg | 27 | 27 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1586 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ticarcillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1587 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ticarcillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1588 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | H.influenzae |
| 1589 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | H.influenzae |
| 1590 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Temocillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1591 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Temocillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1592 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1593 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Phenoxymethylpenicillin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1594 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefepime | NA | 0.25 | 0.25 | FALSE | NA | H.influenzae |
| 1595 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefepime | 30 mcg | 28 | 28 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1596 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefixime | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 1597 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefixime | 5 mcg | 26 | 26 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1598 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefotaxime | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 1599 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefotaxime | 5 mcg | 27 | 27 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1600 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefpodoxime | NA | 0.25 | 0.25 | FALSE | NA | H.influenzae |
| 1601 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefpodoxime | 10 mcg | 26 | 26 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1602 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftaroline | NA | 0.03 | 0.03 | FALSE | NA | H.influenzae |
| 1603 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftaroline | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | H.influenzae |
| 1604 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftibuten | NA | 1 | 1 | FALSE | NA | H.influenzae |
| 1605 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftibuten | 30 mcg | 25 | 25 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1606 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | H.influenzae |
| 1607 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftobiprole | NA | IE | IE | FALSE | NA | H.influenzae |
| 1608 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftolozane-tazobactam (pneumonia) | NA | 0.5 | 0.5 | FALSE | [2] See table of dosages for dosing for different indications. | H.influenzae |
| 1609 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftolozane-tazobactam (pneumonia) | IP mcg | IP | IP | FALSE | [2] See table of dosages for dosing for different indications. | H.influenzae |
| 1610 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftriaxone | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 1611 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftriaxone | 30 mcg | 32 | 32 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1612 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefuroxime iv | NA | 1 | 2 | FALSE | NA | H.influenzae |
| 1613 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefuroxime iv | 30 mcg | 27 | 25 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1614 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefuroxime oral | NA | 0.001 | 1 | FALSE | NA | H.influenzae |
| 1615 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefuroxime oral | 30 mcg | 50 | 27 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1616 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ertapenem | NA | 0.5 | 0.5 | FALSE | NA | H.influenzae |
| 1617 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ertapenem | 10 mcg | 23 | 23 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1618 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Imipenem | NA | 2 | 2 | FALSE | NA | H.influenzae |
| 1619 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Imipenem | 10 mcg | 20 | 20 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1620 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Imipenem-relebactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 1621 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Imipenem-relebactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 1622 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | NA | 2 | 2 | FALSE | NA | H.influenzae |
| 1623 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | 10 mcg | 20 | 20 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | H.influenzae |
| 1624 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | FALSE | NA | H.influenzae |
| 1625 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem(meningitis) | NA | Note | Note | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem. | H.influenzae |
| 1626 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 1627 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem-vaborbactam | NA | IE | IE | FALSE | NA | H.influenzae |
| 1628 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Aztreonam | NA | IE | IE | FALSE | NA | H.influenzae |
| 1629 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Aztreonam | NA | IE | IE | FALSE | NA | H.influenzae |
| 1630 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ciprofloxacin | NA | 0.06 | 0.06 | FALSE | NA | H.influenzae |
| 1631 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ciprofloxacin | 5 mcg | 30 | 30 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 1632 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Delafloxacin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1633 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Delafloxacin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1634 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Levofloxacin | NA | 0.06 | 0.06 | FALSE | NA | H.influenzae |
| 1635 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Levofloxacin | 5 mcg | 30 | 30 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 1636 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Moxifloxacin | NA | 0.125 | 0.125 | FALSE | NA | H.influenzae |
| 1637 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Moxifloxacin | 5 mcg | 28 | 28 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 1638 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Nalidixic acid (screen only) | 30 mcg | 23 | Note | FALSE | [B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | H.influenzae |
| 1639 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ofloxacin | NA | 0.06 | 0.06 | FALSE | NA | H.influenzae |
| 1640 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ofloxacin | 5 mcg | 30 | 30 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 1641 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amikacin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1642 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amikacin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1643 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Gentamicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1644 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Gentamicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1645 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Netilmicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1646 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Netilmicin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1647 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tobramycin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1648 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tobramycin | NA | IE | IE | FALSE | NA | H.influenzae |
| 1649 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Azithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1650 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Azithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1651 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Clarithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1652 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Clarithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1653 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Erythromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1654 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Erythromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1655 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Roxithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1656 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Roxithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1657 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Telithromycin | NA | Note | Note | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1658 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Telithromycin | NA | Note | Note | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1659 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Doxycycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1660 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Doxycycline | NA | Note | Note | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1661 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Eravacycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 1662 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Eravacycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 1663 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Minocycline | NA | 1 | 1 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1664 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Minocycline | 30 mcg | 24 | 24 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1665 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tetracycline | NA | 1 | 2 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1666 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tetracycline | 30 mcg | 25 | 22 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1667 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tigecycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 1668 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tigecycline | NA | IE | IE | FALSE | NA | H.influenzae |
| 1669 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Chloramphenicol | NA | 2 | 2 | FALSE | NA | H.influenzae |
| 1670 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Chloramphenicol | 30 mcg | 28 | 28 | FALSE | NA | H.influenzae |
| 1671 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | H.influenzae |
| 1672 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Fosfomycin iv | NA | IE | IE | FALSE | NA | H.influenzae |
| 1673 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | NA | 1 | 1 | FALSE | NA | H.influenzae |
| 1674 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | 5 mcg | 18 | 18 | FALSE | NA | H.influenzae |
| 1675 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | NA | 0.5 | 1 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | H.influenzae |
| 1676 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 23 | 20 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | H.influenzae |
| 1677 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ampicillin-sulbactam | NA | 1 | 1 | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1678 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ampicillin-sulbactam | NA | Note | Note | FALSE | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1679 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | NA | 1 | 1 | FALSE | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | M.catarrhalis |
| 1680 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | 2/1 mcg | 19 | 19 | FALSE | NA | M.catarrhalis |
| 1681 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1682 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Piperacillin-tazobactam | NA | Note | Note | FALSE | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1683 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ticarcillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 1684 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ticarcillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 1685 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 1686 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 1687 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Temocillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 1688 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Temocillin | NA | IE | IE | FALSE | NA | M.catarrhalis |
| 1689 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefepime | NA | 4 | 4 | FALSE | NA | M.catarrhalis |
| 1690 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefepime | 30 mcg | 20 | 20 | FALSE | NA | M.catarrhalis |
| 1691 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefixime | NA | 0.5 | 1 | FALSE | NA | M.catarrhalis |
| 1692 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefixime | 5 mcg | 21 | 18 | FALSE | NA | M.catarrhalis |
| 1693 | EUCAST 2020 | 10.0 | Clinical Breakpoint Tables v. 10.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefotaxime | NA | 1 | 2 | FALSE | NA | M.catarrhalis |
| The file is too large to be shown. View Raw |